PostScript

HIGHLIGHT

Histopathology of birdshot retinochoroidopathy

Birdshot retinochoroidopathy is a chronic posterior segment inflammatory disease with a characteristic clinical presentation and strong correlation with the HLA-A29 antigen.^{1,2} In this report, we describe the histopathological findings in the eye of a patient with this disease.

Clinical presentation

A 49 year old white man was referred to the Proctor Medical Group in 1996 for evaluation of multifocal choroiditis (MFC). This had been an incidental finding on routine examination by his primary ophthalmologist. The patient was bothered by his refractive error, but denied problems with night or colour vision, and did not notice floaters.

The patient's past ocular history was notable for myopic correction since childhood. Radial keratotomy (RK) had been performed in both eyes in 1993, with subsequent fluctuations in his refraction. His past medical history was notable for a small cutaneous melanoma removed 5 months before presentation. He had been started on oral prednisone for his MFC before his referral to Proctor.

Best corrected visual acuity was 20/20 in both eyes, and the intraocular pressures were

14 mm Hg. External examination was unremarkable, and the anterior segments showed RK scars and no inflammation. Trace vitreous cell was noted in both eyes. The optic nerve heads appeared pink and healthy, and the vasculature was unremarkable.

Multiple cream-coloured round and oval spots were scattered throughout the posterior poles of both eyes, more prominent nasally (Figs 1A and B). The spots averaged approximately 500 µm in diameter, and were deep to the neural retina. The macula in each eye was flat with appropriate pigmentation. The fundus had a very "blond" appearance consistent with the patient's complexion.

An examination for posterior uveitis included angiotensin converting enzyme (ACE) and lysozyme levels, a purified protein derivative (PPD) test, a chest x ray, fluorescent treponemal antibody (FTA) titres, and an HLA panel. The only remarkable finding was the presence of the HLA-A29 antigen. The characteristic fundus appearance together with the HLA-A29 antigen indicated the diagnosis of birdshot retinochoroidopathy.

The patient returned to the care of his primary ophthalmologist, and for the next 6 years perceived no changes in his visual function. Periodic fluorescein angiograms were performed during this period (Figs 1C, D, E), and on these the fundus lesions were much less evident than on clinical examination. No vasculitis, cystoid macular oedema, or optic nerve head inflammation were ever apparent.

In December, 2001, the patient sustained a myocardial infarction and died. In accordance with the patient's wishes, the right eye was enucleated post mortem and sent to the Hogan Eye Pathology laboratory, University of California San Francisco.

Histopathological evaluation

The corneal scleral rim had been harvested (inadvertently, unaware of the history of RK) by a local eye bank. The globe was submitted in formalin and, lacking the cornea, was grossly distorted. A 4 mm segment of optic nerve was attached.

Haematoxylin and eosin staining was used to evaluate the microscopic sections.

The sclera was unremarkable. The anterior segment was markedly distorted as a result of the corneal harvesting, and it was impossible to evaluate the iris and anterior chamber angle. The lens was artefactually luxated. The ciliary body and anterior choroid appeared unremarkable.

Multiple foci of predominantly lymphocytes were located at various levels of the choroid, occasionally occupying the full choroidal thickness, and abutting the choroidal vascular channels (Figs 2A, B, C). Rare plasma cells were seen, and some foci were associated with haemorrhage. A few foci contained epithelioid cells, and there was no necrosis.

The retinal pigment epithelium (RPE) did not appear involved in the underlying choroidal process.

Figure 1 Clinical and fluorescein angiographic (FA) findings. (A) Right eye, posterior pole. (B) Right eye, nasal mid-periphery, showing characteristic birdshot lesions. (C) Red free photograph, right eye nasal mid-periphery. (D) FA, mid-phase, same view as (C). (E) FA, late phase, same view.

Figure 2 Histopathological sections, haematoxylin and eosin staining. (A) Low power photomicrograph showing three foci of lymphocytic infiltrates (arrows) in the choroid ($\times 5$ magnification). (B) Higher power photomicrograph of focal lymphocytic infiltrate in the choroid. The choriocapillaris (top) is not involved ($\times 50$ magnification). (C) Choroidal lymphocytic focus abutting choroidal vessels ($\times 50$ magnification). (D) Lymphocytes surround a retinal vessel (focal retinal vasculitis) ($\times 50$ magnification). (E) Focal lymphocytic infiltrate (arrow) in prelaminar optic nerve ($\times 25$ magnification).

Additional foci of lymphocytes were found surrounding some of the retinal blood vessels (Fig 2D). The neural retina showed no cellular infiltration and appeared normal, although artefactual disorganisation of the photoreceptor outer segments made evaluation of this cell layer inconclusive.

The prelaminar optic nerve head showed an additional lymphocytic focus (Fig 2E), while the remainder of the optic nerve was unremarkable.

Conclusion

This study finds that birdshot retino-choroidopathy is characterised by lymphocytic aggregations with their foci in the deep choroid, with additional foci in the optic nerve head and along the retinal vasculature. In all likelihood, the choroidal foci correspond to the fundus spots for which this condition is well known. These histopathological findings are consistent with the angiographic observations in patients with this condition, and may explain the electroretinographic (ERG)

changes seen in the advanced stages of this disease.

The characteristic fundus spots, light degree of vitreous inflammation, HLA-A29 antigen, and lack of other contributory laboratory findings strongly support the diagnosis of birdshot choroidopathy in this patient. The HLA-A29 antigen is closely associated with this condition,^{1,3} and this association is so well established that the diagnosis of birdshot is increasingly considered problematic without it.

The histopathological description of our patient's eye contrasts with an earlier report describing the histopathology of a blind, phthisical eye believed to have been affected by birdshot choroidopathy.³ That eye showed diffuse granulomatous inflammation in the outer retinal layers, with less inflammation in the choroid. Important differences in clinical presentation between our patient and the patient described in that report include: (1) our patient had the HLA-A29 antigen, while the patient in that report did not; (2) our

patient's eye was neither blind nor phthisical. In light of these differences, the histopathological findings described in this report are probably more characteristic than those reported earlier for this disease.

The fundus lesions in birdshot choroidopathy did not stand out on fluorescein angiography (FA) in this patient, and lack of fluorescence is not uncommon in this condition,¹ and may represent "very early" phases of the birdshot lesions.^{1,4} On histopathology, the neural retina, retinal pigment epithelium, and in many areas the choriocapillaris appeared unaffected by the inflammatory process, and could potentially have obscured fluorescence of the deeper structures.⁴ Many patients with advanced birdshot show optic nerve head inflammation and diffuse retinal vascular leakage on FA.^{4,5} Our patient did not have these findings, although his eye did show a small optic nerve head lymphocyte focus and limited retinal perivascular infiltration. It seems likely that these early changes would have become evident on FA eventually if they had had time to advance.

Indocyanine green (ICG) angiography reveals birdshot lesions as hypofluorescent choroidal patches which outnumber those seen clinically.⁶ These patches most probably correspond to the deep choroidal lymphocytic foci seen microscopically, which are hypofluorescent because they exclude the surrounding deep choroidal vasculature. Presumably, the lymphocytic foci that characterise this condition must achieve a certain diameter, density, and perhaps inward extension before being apparent clinically.

Electroretinogram (ERG) changes characteristic of this disease include a preserved a-wave, with diminished amplitude and increased latency time of the b-wave, suggesting impairment of the inner retina.⁷⁻⁹ Retinal vasculopathy (determined angiographically), rather than the extent of RPE/choroidal complex involvement, has also been noted to correlate with electro-oculogram (EOG) changes.⁷ One may speculate that the retinal perivascular lymphocytic infiltration seen in this patient progresses, in advanced stages, to inner retinal ischaemia with the observed ERG and EOG manifestations. Electroretinography was not undertaken in our patient because initially this was not essential to the diagnosis, and subsequently the patient did not follow up in our referral centre.

This report of histopathological findings in the eye of a patient with birdshot choroidopathy represents the first such description from an HLA-A29 patient. The microscopically observed changes shed light on what the fundus spots in this condition are composed of, and to some extent explain the angiographic finding in this disease.

Funding source: none

The authors have no proprietary interest in this study.

P A Gaudio

Francis I Proctor Foundation, University of California San Francisco, CA, USA

D B Kaye

Natural Vision, Madera, CA, USA

J Brooks Crawford

Hogan Eye Pathology Laboratory, University of California San Francisco, CA, USA

Correspondence to: J Brooks Crawford, MD,
Department of Ophthalmology, UCSF, K-219, Box
0730, 10 Kirkham Street, San Francisco, CA
94143, USA; brooks.crawford@ucsfmedctr.org

Accepted for publication 16 August 2002

References

- 1 Gasch AT, Smith JA, Whitcup SM. Birdshot retinochoroidopathy. *Br J Ophthalmol* 1999;**83**:241–9.
- 2 Ryan SJ, Maumenee AE. Birdshot retinochoroidopathy. *Am J Ophthalmol* 1980;**89**:31–45.
- 3 Nussenblatt RB, Mittal KK, Ryan S, et al. Birdshot retinochoroidopathy associated with HLA-A29 antigen and immune responsiveness to retinal S-antigen. *Am J Ophthalmol* 1982;**94**:147–58.
- 4 LeHoang P, Ryan S. Birdshot retinochoroidopathy. In: Wilhelmus KR, ed. *Ocular infection and immunity*. St Louis: Mosby, 1996:570–8.
- 5 Soubrane G, Bokobza R, Coscas G. Late developing lesions in birdshot retinochoroidopathy. *Am J Ophthalmol* 1990;**109**:204–10.
- 6 De Geronimo F, Glacet-Bernard A, Coscas G, et al. Birdshot retinochoroidopathy: measurement of the posterior fundus spots and macular edema using a retinal thickness analyzer, before and after treatment. *Eur J Ophthalmol* 2000;**10**:338–40.
- 7 Priem HA, De Rouck A, De Laey JJ, et al. Electrophysiologic studies in birdshot chorioretinopathy. *Am J Ophthalmol* 1988;**106**:430–6.
- 8 Hirose T, Katsumi O, Pruett RC, et al. Retinal function in birdshot retinochoroidopathy. *Acta Ophthalmol (Copenh)* 1991;**69**:327–37.
- 9 Kaplan HJ, Aaberg TM. Birdshot retinochoroidopathy. *Am J Ophthalmol* 1980;**90**:773–82.

LETTERS

Retinoblastoma and retinal astrocytoma: unusual double tumour in one eye

In the recent literature there is controversy regarding the histopathological origin of retinoblastoma (RB) and retinal astrocytoma (RA). The common origin of both tumours from a multipotential stem cell has been studied in RB cell lines Y-79 and fresh RB materials with immunohistological techniques using GFAP (glial fibrillary acid protein), NSE (neuron specific enolase), photoreceptor cell markers (S-100, myelin basic protein), and synaptophysin.^{1–8} In immunohistopathological studies indications have been found for differentiation of RB into a neuronal and a partial glial pathway.^{1–8}

To our knowledge no reports have been published on the simultaneous occurrence of both an RB and an RA in one eye. We present a case that demonstrates one eye of a 5 year old girl containing those two immunohistologically different tumours.

Case report

In a 5 year old white girl a divergent strabismus of the right eye was discovered. No family history of RB or phacomatosis was present. Funduscopy examination under anaesthesia showed a central white mass. Nasally inferior in the peripheral retina a second large whitish mass with vitreous seeding on the top was discerned without abnormal vasculature.

On DNA investigation no mutation in the *RBI* gene was found with SSCP (single strand conformational polymorphism) technique.

Enucleation was performed within 1 week after the diagnosis RB was established.

Histologically, the first, most anterior tumour was largely necrotic, but highly cellular (Fig 1A). Only few islands of vital cells with a central blood vessel were seen. The tumour cells had medium sized nuclei, with a very dense chromatin. The nuclear shape was oval to slightly irregular. Cytoplasm was scanty. There were many apoptotic tumour cells, and mitotic figures and occasional calcifications were present (Fig 1B).

The second and more posteriorly situated tumour was quite different. It showed areas with high cellularity, without necrosis. These high cellular areas were separated by areas of low cellularity, that appeared fibrous, or compact fascicular. Many calcifications were present (Fig 2A). The cells in the cellular areas had fairly small round nuclei (though slightly larger than the neuronal cells in the neighbouring retina), with a finely dispersed, somewhat granular chromatin, and occasional nucleoli. The cells in the compact fascicular areas were more spindle-shaped, but with a similar chromatin pattern. No mitotic or apoptotic figures were found (Fig 2B).

Immunohistochemically, the first, peripheral tumour stained positive for synaptophysin and negative for GFAP and neurofilament. The second, central tumour showed a negative synaptophysin, but showed strong staining for GFAP, especially in compact areas. The cells in the cellular areas only occasionally stained positive for GFAP.

Comment

Both the histology and the immunohistochemistry showed two entirely different tumours, one (the anterior tumour) clearly an RB, largely necrotic. In the second tumour, a glioma, with cellular areas resembling oligodendroglioma, the more compact “fibrous” areas resembled a pilocytic astrocytoma.

As the morphology of the two tumours clearly differed the occurrence of a “seedling” of RB, though theoretically possible, in itself is an unusual sequence of events and is not likely here. The differentiation would have increased the staining intensity for synaptophysin and may even have caused a positive neurofilament staining, but in our case both neuronal markers were negative. Also, the growth pattern of the second tumour with its intermingling of small cells (putative retinocytal) and glial components strongly suggest two different tumours.

However, that does not mean these two tumours cannot be related. We feel this case illustrates the discussion whether RB and RA are two totally different tumours, both originating in the retina, or a transitional form of simultaneous expression of neuronal and glial cells from a germline stem cell.^{1–8}

The differentiation between RA and RB and the possible transitional form derived from the specific glial supporting cells (Mueller cell) were investigated on RB Y-79 cell lines and tumour material.^{1–3}

The view that RBs are neuronal tumours, although sporadic cases may show immunohistochemical signs of partial astrocytic or Mueller's cell differentiation, has been supported by several studies.^{2–4–6–8}

In agreement with this finding, Gonzales-Fernandez *et al* report the in situ expression of photoreceptor and glial cell associated proteins in fresh RB tumour material.⁷

Their data suggest that RB has the histogenetic potential of the immature neural retinal epithelium which can give rise to both photoreceptor and Mueller cell lineages.

These studies suggest that indications for differentiation of RB into a neuronal and a partial glial pathway.

In our opinion it has been demonstrated by many studies that both retinal photosensory cells and Mueller glial cells are derived from a neuroretinal epithelium stem cell, with the

Figure 1 Retinoblastoma. (A) Largely necrotic tumour with medium sized, dark stained cells, a typical picture for retinoblastoma (haematoxylin and eosin, $\times 80$). (B) Cellular detail showing medium sized, hyperchromatic nuclei (haematoxylin and eosin, $\times 350$).

Figure 2 Retinal astrocytic tumour. (A) Glioma showing fibrillary areas and more hypercellular areas closely intermingled here; many calcifications are present (haematoxylin and eosin, $\times 80$). (B) Nuclei are small and somewhat elongated. Their chromatin is somewhat finer, than in the first tumour (haematoxylin and eosin, $\times 350$).

capacity of different expression by immature retinal cells. Perhaps the occurrence of a double tumour, as our case, is therefore not so surprising. However, this case suggests, showing the clinical form of different expression of a germline retinal neuroectodermal stem cell, that differentiation of immature retinal cells could be a tightly regulated process.

S M Imhof, A C Moll

Department Ophthalmology, University Hospital
Vrije Universiteit, Amsterdam, Netherlands

P Van Der Valk

Department of Pathology, University Hospital Vrije
Universiteit, Amsterdam, Netherlands

A Y N Schouten-van Meeteren

Department of Pediatric Oncology, University
Hospital Vrije Universiteit, Amsterdam, Netherlands

Correspondence to: Saskia M Imhof, Department of
Ophthalmology, University Hospital Vrije
Universiteit, De Boelelaan 1117, NL-1081 HV
Amsterdam, Netherlands; s.imhof@azvu.nl

Accepted for publication 26 December 2002

References

- 1 **Kyritsis AP**, Tsokos M, Triche TJ, *et al*. Retinoblastoma—origin from a primitive neuroectodermal cell? *Nature* 1984;**307**:471–3.
- 2 **Molnar M**, Stefansson K, Marton LS, *et al*. Immunohistochemistry of retinoblastomas in humans. *Am J Ophthalmol* 1984;**97**:301–7.
- 3 **Tsokos M**, Kyritsis AP, Chader GJ, *et al*. Differentiation of human retinoblastoma in vitro into cell types with characteristics observed in embryonal or mature retina. *Am J Pathol* 1986;**123**:542–52.
- 4 **Char DH**, Wood IS, Huhta K, *et al*. Retinoblastoma: tissue culture lines and monoclonal antibody studies. *Invest Ophthalmol Vis Sci* 1984;**25**:30–40.
- 5 **Messmer EP**, Font RL, Kirkpatrick JB, *et al*. Immunohistochemical demonstration of neuronal and astrocytic differentiation in retinoblastoma. *Ophthalmology* 1985;**92**:167–73.
- 6 **Rodrigues MM**, Wiggert B, Shields JA. Retinoblastoma: immunohistochemistry and cell differentiation. *Ophthalmology* 1987;**94**:378–87.
- 7 **Gonzales-Fernandez F**, Lopes MBS, Garcia-Fernandez JM, *et al*. Expression of developmentally defined retinal phenotypes in the histogenesis of retinoblastoma. *Am J Pathol* 1992;**141**:363–75.
- 8 **Xu KP**, Liu SL, Ni C. Immunohistochemical evidence of neuronal and glial differentiation in retinoblastoma. *Br J Ophthalmol* 1995;**79**:771–6.

Artefactual uniocular altitudinal visual field defect

Altitudinal visual field defects are commonly associated with ischaemic optic neuropathy and hemibranch artery or vein occlusion. Less commonly, altitudinal visual field defects can be seen in advanced glaucoma. Artefactual visual field defects are not uncommon; however, to our knowledge this is the first reported case of an artefactual uniocular altitudinal visual field defect due to an abnormally sensitive hemifield response with the automated Humphrey perimeter.

Case report

A healthy 61 year old woman was referred to the ophthalmology department by her optician who had noted a visual field defect in her left eye following a routine examination. The patient was asymptomatic and her past ocular history was unremarkable. Initial assessment of the visual field carried out by the optician appeared to show a superior altitudinal field

defect in the left eye (Fig 1). Ocular examination revealed 6/5 corrected vision and normal intraocular pressures in either eye. There was no relative afferent pupil defect and both optic discs were healthy. Fundus examination was otherwise unremarkable. Confrontational visual field test failed to show any defect. Goldmann visual field testing confirmed normal fields in both eyes. Closer examination of the Humphrey field test carried out by the optician shows the defect to be artefactual.

Comment

Altitudinal visual field defects are most commonly associated with ischaemic optic neuropathy and hemibranch artery or vein occlusion. They can also be seen in patients with glaucoma, chiasmal lesions, and optic nerve lesions such as colobomas. Hysterical or malingering patients and individuals deliberately attempting to mislead the Humphrey machine can manifest visual field defects including altitudinal defects on perimetry.^{1,2}

In this reported case the pattern deviation plot initially appears to show a superior altitudinal field defect. However, scrutiny of the threshold sensitivities on the grey scale data reveals that the patient had somehow achieved abnormally high sensitivities in the inferior hemifield only (highest value 50 dB). The threshold sensitivities for the superior hemifield appear normal to slightly high (highest value 37 dB). Hence the pattern deviation defect is not only artefactual but also paradoxical. One can only speculate as to the cause of this artefactual field defect. Patient anxiety often leads to false positive responses and this patient had 67% false positive errors. However, it is curious that this should occur in one hemifield and in one eye only. One must always consider the possibility of either technical problem in stimulus presentation or machine software problems in unexplained or anomalous visual field defects. However, it is difficult to explain the pattern of this visual field defect on the basis

Single Field Analysis

Figure 1 Humphrey visual field of the left eye showing the "apparent" altitudinal field defect.

© 1994–98 Humphrey Systems
HFA II 720–3401–A10.1

of machine failure. This case demonstrates the importance of looking at the pattern deviation in conjunction with the grey scale, threshold sensitivities and interpreting the visual field in the light of other clinical data.

V Kumar, U S Ramanathan, B Mushtaq, P Shah

Birmingham and Midland Eye Centre,
Birmingham, UK

Correspondence to: Mr Peter Shah, Birmingham and Midland Eye Centre, City Hospital NHS Trust, Dudley Road, Birmingham B18 7QH, UK

Accepted for publication 15 May 2002

References

- 1 Thompson JC, Kosmorsky GS, Ellis BD. Fields of dreamers and dreamed-up fields. *Ophthalmology* 1996;**103**:117–25.
- 2 Stewart JFG. Automated perimetry and malingers. Can the Humphrey be outwitted? *Ophthalmology* 1995;**102**:27–32.

Bilateral acute anterior uveitis after alendronate

Biphosphonates are increasingly being used for the prevention and treatment of osteoporosis in women where hormone replacement therapy is contraindicated.^{1,2} Alendronate (Fosamax) is a potent aminobiphosphonate that reduces bone resorption and increases bone mass and therefore reduces the incidence of fractures in postmenopausal women with osteoporosis.² The most common adverse effects are upper gastrointestinal, including dysphagia, heartburn, oesophagitis, and oesophageal strictures. We report a case of bilateral acute anterior uveitis following the use of alendronate (once weekly 70 mg tablet). This is the first reported case of bilateral acute anterior uveitis associated with alendronate.

Case report

A 57 year old woman had been taking oral alendronate 10 mg daily for a year without experiencing any eye problems. To simplify the regimen her general practitioner proposed a single weekly dose of 70 mg. Two days after the first dose she developed a painful left eye and was seen by an ophthalmologist in Russia. She was diagnosed with left kerato-uveitis and was prescribed topical atropine, dexamethasone and ciprofloxacin, and oral azithromycin. On her return to England 3 days later she was seen in our eye casualty department where she was noted to have bilateral anterior uveitis.

Her past ocular history was unremarkable. Her past medical history revealed that she had undergone bilateral mastectomies in 1995 for a right invasive intraductal carcinoma. Before that she had been taking hormone replacement therapy.

She was advised to continue with topical dexamethasone to her left eye and topical dexamethasone and cyclopentolate were started to her right eye. Results of a full blood count, erythrocyte sedimentation rate, blood urea, electrolytes, ANA, and chest x ray were normal. Alendronate was discontinued and on follow up examination 2 weeks later the iritis had resolved in both eyes. Subsequent evaluations have been stable with no recurrent iritis.

Comment

Biphosphonates have previously been associated with various ocular inflammatory side effects specifically, iritis, scleritis, and orbital myositis.^{3–5} Uveitis seems to be peculiar to

nitrogen-containing biphosphonates, although the mechanism by which they cause anterior uveitis is not clear. A woman who had previously tolerated etidronate, a non nitrogen-containing biphosphonate suffered from bilateral iritis in relation to two nitrogen-containing biphosphonates, resdronate and pamidronate. The iritis resolved with steroid drops and discontinuation of aminobiphosphonates.³

Alendronate is a third generation aminobiphosphonate commonly used for the treatment and prevention of postmenopausal osteoporosis. Mbekeani *et al* reported three cases of alendronate associated anterior and posterior scleritis and orbital myositis.⁴ Only one of these patients also developed unilateral iritis, which responded to steroids and discontinuation of alendronate.

In high doses alendronate is associated with acute phase reactions, characterised by transient fever, lymphocytopenia, elevation of C reactive protein, interleukin 1, and interleukin 6. Alendronate may affect these inflammatory mediators, thereby indirectly stimulating ocular inflammation.

Alendronate is not metabolised in the body it is either sequestered in the bone or excreted exclusively through the kidney. We hypothesise that our patient developed bilateral anterior uveitis so soon after taking the higher dose because of a cumulative effect.

The gastrointestinal absorption of alendronate is low. As the gastrointestinal adverse effects appear to be related to the poor solubility of alendronate, the manufacturers recommend that the tablet should be swallowed whole with a full glass of water on an empty stomach at least 30 minutes before breakfast. The patient is also instructed to stand or sit upright for 30 minutes after taking the dose. On account of these strict instructions many women may prefer to switch to the once weekly 70 mg tablet rather than the daily 10 mg tablet.

An ophthalmologist can only safely prescribe treatment of uveitis. General practitioners should be aware that uveitis might develop in patients on alendronate. This risk may be increased in those who are commenced on the higher dose, so that prompt referral can be made to an ophthalmologist.

This report will make the ophthalmic community more aware of this potential complication with alendronate.

A R Malik, S H Campbell, N M G Toma

Moorfields Eye Hospital, City Road,
London EC1V 2PD, UK

Correspondence to: Dr Malik;
amber_r_malik@hotmail.com

Accepted for publication 15 May 2002

References

- 1 Colditz GA, Hankinson SE, Hunter DJ, *et al*. The use of estrogen and progestins and the risk of breast cancer in post menopausal women. *N Engl J Med* 1995;**332**:1589–93.
- 2 Liberman UA, Weis SR, Broll J, *et al*. Effect of alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. *N Engl J Med* 1995;**333**:1437–43.
- 3 Siris ES. Biphosphonates and iritis. *Lancet* 1993;**341**:436–7.
- 4 Mbekeani NJ, Slamovits LT, Schwartz HB, *et al*. Ocular inflammation associated with alendronate therapy. *Arch Ophthalmol* 1999;**117**:837–8.
- 5 Ghose K, Waterworth R, Trolove P, *et al*. Uveitis associated with pamidronate. *Aust NZ J Med* 1994;**24**:320.

Effect of a YAG laser iridotomy on intraocular pressure in pigmentary glaucoma

Pigmentary glaucoma (PG) is characterised by the liberation of pigment from the iris pigment epithelium and its deposition on various anterior segment structures.¹ The accumulation of pigment in the aqueous outflow system can result in an increase in intraocular pressure (IOP) and eventual glaucoma. Campbell² proposed that mechanical rubbing between the concave posterior iris surface and the zonular bundles is responsible for the release of pigment granules from the iris pigment epithelium. Laser iridotomy was proposed to eliminate the reverse papillary block mechanism of pigment dispersion syndrome (PDS).³ Using ultrasound biomicroscopy (UBM) laser iridotomy has been shown to alter the iris configuration in PDS patients.^{4,5} However, the effect of a laser iridotomy on IOP in PG is not clear. Here we present a case of PG with active pigment release, in which substantially lower IOPs were achieved for a short period following a yttrium-aluminium-garnet (YAG) laser iridotomy.

Case report

A 36 year old male patient was referred from an optometrist for high IOPs and visual field loss in 29 January 2001. We saw this young man on 6 February 2001. He denied any systemic disease or family history for blindness or glaucoma. The only medication taken was Propecia for treating hair loss for the past 1½ years. His visual acuity was 20/25 +1 in the right eye and 20/20 in the left eye. IOPs were 54 mm Hg in the right eye and 52 mm Hg in the left by applanation. Slit lamp examination was remarkable for Krukenberg's spindles; anterior chambers that were very deep with 3+ pigment debris; and irides demonstrating radial transillumination defects and posterior bowing. Gonioscopy revealed grade 4 anterior chamber angles with very heavy trabecular meshwork pigmentation and a Sampoclesi's line in both eyes. Fundus examination showed cup:disc ratios of 0.8 bilaterally.

Combination timolol/trusopt and brimonidine were started in both eyes to lower the pressure. UBM examination on 9 March (Fig 1A) demonstrated posterior iris bowing and a relatively large zone of iris-lens contact. A YAG laser iridotomy was performed in the right eye 1 week afterwards and UBM examination showed a planar iris configuration following the laser iridotomy (Fig 1B). IOPs were 32 mm Hg in both eyes immediately before the laser. Three days later, IOPs were 17 mm Hg in the right eye and 34 mm Hg in the left. Examination revealed no anterior chamber pigment debris in the right eye and persistent pigment debris in the left. A YAG laser iridotomy was performed in the left eye on 16 March. One week later, IOPs were 25 mm Hg in the right and 18 mm Hg in the left with no pigment debris in the anterior chambers of both eyes. IOPs remained in the 20s in both eyes for several weeks. However, the IOP had risen to 28 mm Hg in the right eye and 24 mm Hg in the left on 4 April and bimatoprost was added to the glaucoma regimen of both eyes. Four months after laser therapy, the IOPs were 21 mm Hg in the right and 22 mm Hg in the left. On 4 September the IOPs were 27 mm Hg in the right eye and 23 mm Hg in the left. To prevent further increase in his IOP and optic nerve damage, Ahmed valve implantation combined with mitomycin C application was performed in the right eye on 16 November. Subconjunctival injections of

Figure 1 (A) UBM image showing the iris concavity before iridotomy. (B) UBM image showing flattening of the iris configuration following iridotomy in the same eye.

5-fluorouracil were given weekly for 6 weeks after the operation. Two months postoperatively, IOPs were 24 mm Hg in the right eye and 30 mm Hg in the left with only the left eye receiving glaucoma therapy. Filtering surgery is planned for the left eye.

Comment

In PDS, the accumulation of pigment can overwhelm the aqueous outflow system, causing trabecular occlusion and collapse, and an increase in IOP. An iridotomy may be effective in stabilising the iris configuration by reducing the IOP gradient between the anterior and the posterior chamber. Consequently, there would be a lower chance of iridozonular contact and pigment release. Using UBM, Potash *et al*⁴ and Lagreze and Funk⁵ showed the presence of iris concavity and iridozonular contact in PDS patients and demonstrated that laser iridotomy can restore a normal iris configuration. It has been suggested that an iridotomy might reduce the incidence of ocular hypertension in eyes affected by PDS.⁶

The ideal initial approach to treat PG is to eliminate the source of IOP elevation. Before YAG laser iridotomy, our patient had shown posterior iris bowing and constant pigment release, demonstrated by the 3+ pigment debris in the anterior chamber. After YAG laser iridotomy, he no longer had pigment debris in the anterior chamber. The iris moved forward to the planar position, which was clearly demonstrated by UBM imaging. The true mechanism for the pressure lowering is unknown. The iridotomy may reduce the pressure by ending the chronic irritation (and consequent inflammation) to the iris from the zonular rubbing and from the iris being stretched in the bowed position. Another possibility is that aqueous suppression has a role in the temporary improvement of IOP shortly following the iridotomy. A further mechanism may be that phagocytosis by the trabecular meshwork cells cleared much of the remaining pigment granules in the intertrabecular spaces. This may have temporarily reduced the outflow obstruction and lowered the IOPs. Our patient had shown lower IOPs for a short period following YAG laser iridotomy. In young patients who show constant active pigment release, laser iridotomy seems to have an effect on the short term IOP control and may have possible long term benefits.

M J Chen, S C Lin

Department of Ophthalmology, University of California San Francisco, California, USA

M J Chen

Department of Ophthalmology, Taipei Veterans General Hospital, National Yang-Ming University, Taiwan, ROC

Correspondence: Shan C Lin MD, Department of Ophthalmology, University of California-San Francisco, 10 Koret Way, San Francisco, CA 94143-0730, USA; shanl@itsa.ucsf.edu

Accepted for publication 20 May 2002

References

- 1 **Sugar HS.** Pigmentary glaucoma: a 25-year review. *Am J Ophthalmol* 1966;62:499–507.
- 2 **Campbell DG.** Pigmentary dispersion and glaucoma: a new theory. *Arch Ophthalmol* 1979;97:1667–72.
- 3 **Karickhoff JR.** Pigmentary dispersion syndrome and pigmentary glaucoma: a new mechanism concept, a new treatment and a new technique. *Ophthalmic Surg* 1992;23:269–77.
- 4 **Potash SD, Tello C, Liebmann J, et al.** Ultrasound biomicroscopy in pigment dispersion syndrome. *Ophthalmology* 1994;101:332–9.
- 5 **Lagreze WD, Funk J.** Iridotomy in the treatment of pigmentary glaucoma: documentation with high resolution ultrasound. *German J Ophthalmol* 1995;4:162–6.
- 6 **Gandolfi SA, Vecchi M.** Effect of a YAG laser iridotomy on intraocular pressure in pigment dispersion syndrome. *Ophthalmology* 1996;103:1693–5.

Rhodotorula rubra endophthalmitis in an HIV positive patient

Rhodotorula species are imperfect basidiomycetous yeasts belonging to the family Cryptococcaceae and are widespread throughout nature.¹ In many clinical situations *Rhodotorula* spp are considered a contaminant, but when identified in normally sterile sources such as blood, cerebrospinal fluid and vitreous the cultures are significant for mycotic infection.¹ Human disease is extremely rare with *Rhodotorula* spp but opportunistic cases of endocarditis, septicaemia, meningitis, ventriculitis, and peritonitis are reported in the literature.² Ocular infections include chronic dacryocystitis,³ keratitis,⁴ chronic postoperative endophthalmitis,⁵ and corneal lamellar graft infection.⁶ It is becoming increasingly important to clinically recognise and consider such opportunistic organisms as an increasing number of patients are immunocompromised by either iatrogenic or disease related causes. Immunocompromised status, indwelling catheters, recent surgery of

trauma, and injecting drug use appear to be the major factors leading to infection.^{1–7} This report presents a case of endogenous *Rhodotorula rubra* infection in an HIV positive male.

Case report

A 26 year old man was referred to the Ottawa Eye Institute by the infectious disease department with a 6 week history of floaters and a 2 week history of minor pain, tearing, injection, and decreasing vision in the right eye. Vision had declined to hand movements 1 week before examination. He was systemically asymptomatic, afebrile, and had no localising symptoms.

Past medical history was significant for injecting drug use, a diagnosis of HIV with concomitant lung abscess in 1991, and osteomyelitis of the L3 vertebrae in 1999. He had no previous ocular history. He was taking 95 mg of methadone daily and denied use of antiretroviral medications. He has an 11 pack year smoking history and denied alcohol use.

Review of systems disclosed multiple track marks on both arms, but was otherwise unremarkable. Best corrected visual acuity was hand movements in the right eye and 20/20 in the left eye. Four plus cells were present in the anterior chamber and vitreous cavity of the right eye. Multiple superficial creamy retinal, vitreous, and anterior chamber infiltrates were present. He was admitted to hospital and started on intravenous amphotericin B 1 mg/kg daily. Vitreous cultures, blood cultures, urine cultures, and a chest x ray was performed.

No improvement was appreciated 2 days after presentation and intravitreal injection of amphotericin B, vancomycin, and tobramycin was performed. The patient refused vitrectomy at this time. Blood cultures, urine cultures, and chest x ray were normal. The patient was discharged home with close monitoring. He was partially compliant with a homatropine and steroid eye drop regimen. Cultures of the vitreous aspirate grew *Rhodotorula rubra* on the fifth day after culture and the specimen was sent to the provincial laboratory for confirmation. The patient showed no improvement clinically. An intravitreal injection of amphotericin B was repeated. Examination at this time disclosed significant posterior synechiae, iris bombe, and numerous vitreous cells adherent to the posterior lens capsule. No view of the fundus was possible. A B-scan disclosed an open funnel retinal detachment. A vitrectomy was offered with guarded prognosis. The patient now accepted this procedure. Following vitrectomy the vision became no light perception and a total non-repairable retinal detachment was present. Provincial laboratory results confirmed infection with *Rhodotorula rubra*. Enucleation was offered because of concern about dissemination of fungus systemically.

Comment

Endogenous endophthalmitis accounts for 2–15% of all endophthalmitis cases and fungi account for over half of all cases.⁸ Fungaemia leads to metastatic seeding of organisms in the choroid and subsequent intraocular infection, although in many cases the patient is systemically asymptomatic and blood cultures may be negative. Bilateral involvement is present in 25% of cases.⁹ Despite current antibiotic therapy and surgical advances the prognosis for patients with endogenous endophthalmitis remains disappointing because of factors such as organism virulence, compromised host status, and delay in diagnosis.¹⁰ The best treatment regimen is unresolved with reports of amphotericin B,

5-fluorocytosine, and a combination of both medications¹ with or without vitrectomy. Despite aggressive medical and surgical management our patient was eventually offered enucleation as the eye had no light perception and was a possible nidus for infection. Future investigations into prevention, optimal diagnostic techniques, and appropriate management are needed.

A B Merkur, W G Hodge

University of Ottawa Eye Institute, 501 Smyth Road,
Ottawa, Ontario K1H 8L6, Canada

Correspondence to: W G Hodge;
whodge@ottawahospital.on.ca

Accepted for publication 24 May 2002

References

- 1 **Gyaurgieva OH**, Bogomolova TS, Gorshkova GI. Meningitis caused by *Rhodotorula rubra* in an HIV-infected patient. *J Med Vet Mycol* 1996;**34**:357–9.
- 2 **Lui AY**, Turett GS, Karter DL, et al. Amphotericin B lipid complex therapy in an AIDS patient with *Rhodotorula rubra* fungemia. *Clin Infect Dis* 1998;**27**:892–3.
- 3 **Muralidhar S**, Sulthana CM. *Rhodotorula* causing chronic dacryocystitis: a case report. *Indian J Ophthalmol* 1995;**43**:196–8.
- 4 **Guerra R**, Cavallini GM, Longanesi L, et al. *Rhodotorula glutinis* keratitis. *Int Ophthalmol* 1992;**16**:187–90.
- 5 **Gregory JK**, Haller JA. Chronic postoperative *Rhodotorula* endophthalmitis. *Arch Ophthalmol* 1992;**110**:1686–7.
- 6 **Panda A**, Pushker N, Nainiwal S, et al. *Rhodotorula* sp infection in corneal interface following lamellar keratoplasty—a case report. *Acta Ophthalmol Scand* 1999;**77**:227–8.
- 7 **Kiehn TE**, Gorey E, Brown AE, et al. Sepsis due to *Rhodotorula* related to use of indwelling central venous catheters. *Clin Infect Dis* 1992;**14**:841–6.
- 8 **Braun DK**, Kauffman CA. *Rhodotorula* fungemia: a life-threatening complication of indwelling central venous catheters. *Mycoses* 1992;**35**:305–8.
- 9 **Kresloff MS**, Castellarin AA, Zarbin MA. Endophthalmitis. [Review] [319 refs] *Surv Ophthalmol* 1998;**43**:193–224.
- 10 **Essman TF**, Flynn HW Jr, Smiddy WE, et al. Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis. *Ophthalmic Surg Lasers* 1997;**28**:185–94.

Ultrasound biomicroscopy: “fisherman’s tale”

Ultrasound biomicroscopy (UBM) has been proved to be a valuable investigative tool in the evaluation of suspected anterior segment ocular foreign bodies.¹ This is especially so in cases involving small, non-metallic objects and where the foreign body is not visible by slit lamp biomicroscopic examination or where a clear history of trauma is not forthcoming.

Case report

A 51 year old fisherman presented to the ophthalmic casualty department with a 2 week history of localised discomfort and redness on the temporal aspect of his right eye. He had no significant ophthalmic history and did not give a history of trauma.

Slit lamp examination of the anterior segment was unremarkable on the left side and revealed an inflamed nodular mass on the temporal aspect of the right sclera (Fig 1).

There was no visible foreign body or conjunctival tear in that region. At this point the suspected clinical diagnoses included inflammatory nodular scleritis and a lymphoma or other neoplastic mass. The

Figure 1 Anterior segment slit lamp photograph showing an inflamed nodular mass on the temporal side of the patient's right eye at presentation.

patient was referred to the ophthalmic ultrasound clinic for UBM (Fig 2).

UBM revealed a high reflectivity discrete echo source (arrow) embedded deep in the sclera, surrounded by a low reflective mass (granuloma).

The appearance was consistent with a foreign body and, on direct questioning, the patient admitted to possible injury while filleting fish on his boat. An excisional biopsy was performed under local anaesthesia. Post-operative recovery was uneventful on a topical regimen of Betnesol-N eye ointment four times daily for 2 weeks; the patient's symptoms ceased after that.

Serial sectioning and histopathological examination were carried out. This revealed a florid foreign body granulomatous reaction directed against some degenerate material of animal origin. In several levels a barbed cellular structure highly suggestive of a fishscale was seen (Fig 3).

Comment

UBM is a high resolution ultrasound using high frequency transducers (50–100 MHz) that was developed by Pavlin *et al* in 1990.² It is a non-specific imaging technique that allows a highly magnified image of the anterior segment to be obtained. It is capable of producing images in the living human eye to a depth of approximately 4 mm at an axial and lateral resolution approaching 20 µm.²

The high resolution provided by this technique combined with its non-invasive and non-ionising nature make UBM a very attractive investigational method in the evaluation of suspected anterior segment foreign bodies. This

Figure 2 UBM recording showing a high reflectivity discrete echo source (arrow) embedded deep in the sclera, surrounded by a low reflectivity mass (granuloma). C = conjunctiva S = sclera.

Figure 3 Histopathological examination showing a foreign body suggestive of a fishscale.

is so even when no clearcut history of trauma is forthcoming as evidenced by this fisherman's tale and the fact that UBM has been used successfully in the past to demonstrate ocular surface and intraocular foreign bodies.^{2,3}

In this case UBM enabled us to obtain sub-surface images of the conjunctiva and sclera at the area of interest that was not possible with slit lamp biomicroscopy. It actually influenced management by raising the suspicion of a foreign body and justifying an excisional biopsy and its subsequent deeper histological sectioning when, clinically, a provisional diagnosis of conjunctival lymphoma or another neoplasm was being pursued that would not have necessarily been treated by an excisional biopsy.

We recommend the use of UBM in some cases of suspected foreign bodies in the sub-surfaces of the conjunctiva and sclera when the nature and extent of the lesion is in doubt.

Sources of funding: None.

Proprietary or financial interest: None.

K Taherian

Department of Ophthalmology, Aberdeen Royal Infirmary, Aberdeen, UK

J M MacKenzie

Department of Pathology

H R Atta

Department of Ophthalmology

Correspondence to: Mr H R Atta, Aberdeen Royal Infirmary, Forresterhill, Aberdeen AB25 2ZN, UK; hatem.atta@arh.grampian.scot.nhs.uk

Accepted for publication 29 May 2002

References

- 1 **Deramo VA**, Shah GK, Bauman CR, et al. Ultrasound biomicroscopy as a tool for detecting and localizing occult foreign bodies after ocular trauma. *Ophthalmology* 1999;**106**:301–5.
- 2 **Pavlin CJ**, Harasiewicz K, Shearer MD, et al. Clinical use of ultrasound biomicroscopy. *Ophthalmology* 1991;**98**:287–95.
- 3 **Chakrabarti HS**, Atta HR. Use of ultrasound biomicroscopy in the localisation and management of an anteriorly situated intraocular foreign body. *Br J Ophthalmol* 1998;**82**:456.

Rapid improvement of chronic interstitial keratitis with acitretin

Acitretin, a synthetic aromatic retinoid which regulates the proliferation, differentiation, and keratinisation of epidermal cells, is usually used to treat severe psoriasis or ichthyosis. The main side effects are teratogenesis and mucocutaneous forms of xerosis such as cheilitis and blepharoconjunctivitis.^{1,2} The biological effects of acitretin in non-epidermal cell lines, and

Figure 1 Right cornea: before (A) and after (B) acitretin therapy for psoriasis.

especially those derived from ocular tissues,^{3,4} could explain the beneficial actions of acitretin in diseases other than skin disorders. We report a drastic improvement in tuberculosis related interstitial keratitis in a patient treated with acitretin for severe psoriasis.

Case report

A 21 year old Moroccan man was referred to our ophthalmology department in 1992 with severe chronic bilateral interstitial keratitis associated with skin lesions. Initial examination revealed epidermal lesions clinically and histologically consistent with pustular psoriasis. The patient also had a history of tuberculosis, with likely onset at age 3 months and first treatment at age 7 years, with isoniazid, rifampicin, and streptomycin. Visual acuity was 20/400 in both eyes. Slit lamp examination revealed confluent interstitial opacities in both corneas, hindering examination of the anterior and posterior segments of the eyes. From 1992 to 1997, successive treatment courses with calcipotriol, psoralene, plus ultraviolet A irradiation and methotrexate for the skin lesions failed to improve the ocular lesions, and neither did steroid therapy given to control systemic signs of inflammation. The patient underwent keratoplasty of the left eye in 1993 to restore a degree of vision. Graft failure occurred after a few months, owing to poor compliance with ocular treatment and/or to periods of ocular inflammation during exacerbations of the skin disease. Another two corneal grafts were attempted in the left eye during the subsequent 3 years, with poor long term results. The left eye became blind and painful and was removed. Surgery was not attempted on the right eye.

In 1998, treatment was started with acitretin (30 mg/day for 1 month, then 20 mg/day) because of a relapse of the skin disease. Within 1 month acuity in the right eye had improved to 20/100 and there was a marked improvement in corneal interstitial opacities (see Fig 1). For the first time in 6 years, detailed examination of the anterior and posterior segments of the eye was possible. Synchiae were observed from the iris to the lens, together with posterior opacities in the lens, likely secondary to previous episodes of ocular inflammation. The aspect of the retina was normal. Two years after the outset of acitretin treatment, the right cornea remains clear.

Comment

Both the rapid improvement in the interstitial keratitis following acitretin introduction for this patient's skin lesions, and the fact that none of the previous treatments for the psoriasis had improved the ocular lesions, strongly suggest that acitretin may be beneficial in some patients with sight threatening corneal opacities. This may be explained by the activity of acitretin on corneal cells, as suggested by experimental studies³ and by a case report of acitretin related keratoconus.⁵ Further laboratory studies and clinical trials are needed to determine whether the adverse effects of acitretin are offset by its beneficial action in chronic interstitial keratitis.

M Labetoulle, H Offret

Department of Ophthalmology, Hôpital de Bicêtre, Assistance Publique-Hôpitaux de Paris, 94275 Le Kremlin-Bicêtre Cedex, France

I Bournerias

Department of Dermatology, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, 94010 Creteil Cedex, France

E Frau

Department of Ophthalmology, Hôpital de Bicêtre, Assistance Publique-Hôpitaux de Paris, 94275 Le Kremlin-Bicêtre Cedex, France

Correspondence to: Marc Labetoulle, Service d'Ophthalmologie, Hôpital de Bicêtre, 94275, Le Kremlin-Bicêtre Cedex, France; marc.labetoulle@gv.cnr-s-gif.fr

Grant supports: None.
Proprietary interest: None.

Accepted for publication 29 May 2002

References

- 1 Katz HI, Waalen J, Leach EE. Acitretin in psoriasis: an overview of adverse effects. *J Am Acad Dermatol* 1999;**41**:S7-12
- 2 Denis P, Nordmann JP, Saiag P, et al. Chronic blepharoconjunctivitis during a treatment with acitretin (Soriatane). *J Fr Ophthalmol* 1993;**16**:191-4.
- 3 Ubels JL, Woo EM, Curley RW Jr. N-linked glycoside and glucuronide conjugates of the retinoid, acitretin, are biologically active in cornea and conjunctiva. *J Ocul Pharmacol Ther* 1998;**14**:505-16.
- 4 Immonen I, Siren V, Stephens RW, et al. Retinoids increase urokinase-type plasminogen activator production by human retinal pigment epithelial cells in culture. *Invest Ophthalmol Vis Sci* 1993;**34**:2062-7.
- 5 Gronhoj LF, Andersen SR, Weismann K, et al. Keratoconus as a possible side-effect of acitretin (neotigason) therapy. *Acta Derm Venereol* 1993;**73**:156.

Figure 1 Central retinal vein occlusion. visual acuity, 20/200. Left, colour photograph. Note the large atrophic chorioretinal scar in the superotemporal area. Right, fluorescein angiogram in the area of the scar (indicated by the square in the colour photograph) showing that there is no detectable communication between retinal and choroidal circulations.

Peripheral retinochoroidal anastomosis after central retinal vein occlusion

Central retinal vein occlusion (CRVO) may lead to the spontaneous formation of shunt vessels running over the optic nerve head.¹ This may contribute to improve retinal venous drainage. The occurrence of shunt vessels elsewhere in the fundus in these patients has not been reported yet. We report here a case of retinochoroidal venous anastomosis through a peripheral chorioretinal scar that revealed itself after the occurrence of CRVO, suggesting that elevated retinal venous pressure triggered the creation of the venous bypass.

Case report

A 70 year old man presented in our department with loss of vision in the left eye which had started 2 months previously. At presentation, visual acuity was 20/200. Fundus examination showed the presence of dilated veins and scattered haemorrhages in four retinal quadrants associated with macular oedema. In addition, in the superotemporal area a large atrophic chorioretinal scar underlying the superotemporal retinal vein was present (Fig 1, left). The patient had no history of eye trauma, inflammation, or photocoagulation. Fluorescein angiography showed that within the scar there was no detectable connection between the arterial and choroidal circulations (Fig 1, right). At a control examination 1 month later, the superotemporal vein overlying the scar was interrupted (Fig 2, left). ICG videoangiography demonstrated that the superotemporal retinal vein was anastomosed to the underlying choroidal vein, with drainage of upstream but not downstream venous blood (Fig 2, right). At that time, rubeosis iridis was present, associated with widespread capillary non-perfusion. Retinal panphotocoagulation was performed which led to regression of rubeosis. Final visual acuity was 20/200.

Comment

Shunt vessels over the disc are frequently observed after CRVO.¹ They are possibly caused by the elevation in capillary pressure that dilates pre-existent retino-opticociliary capillaries. Shunt vessels occurring outside of the disc have been reported in association to a chorioretinal scar,² but to our knowledge not during CRVO. In our case, pre-existing

Figure 2 Same patient 1 month later. Left, colour photograph. Within the scar the overlying superotemporal vein is interrupted. Right, ICG angiography showing the anastomosis between the retinal and choroidal venous circulation through the scar.

retinochoroidal anastomosis or choroidal new vessels may have been present within the scar before CRVO until the increased retinal venous pressure due to CRVO increased the retinochoroidal flow through the scar. However, on the first fluorescein angiogram, there is no evidence of pre-existing anastomosis or new vessels. We therefore cannot conclude on the precise mechanism relying the anastomosis to the CRVO. The anastomosis did not appear to have significantly improved upstream or downstream venous drainage. Moreover, there was occlusion of the venous segment downstream of the anastomosis site. This indicates, as observed after laser induced chorioretinal anastomosis, that anterograde and retrograde drainage is not always present together in the anastomosis site. This may be because a higher difference in pressure between retinal and choroidal veins is needed to promote retrograde drainage.

The authors have no proprietary interest in the present study.

M Paques, A Gaudric

Department of Ophthalmology of the Hôpital Lariboisière, Assistance-Publique-Hôpitaux de Paris, Université Paris VII, Paris, France

Correspondence to: Michel Paques, MD, PhD, Department of Ophthalmology, Hôpital Lariboisière, 2 rue Ambroise Paré, 75745 Paris Cedex 10, France; michel.paques@lrb.ap-hop-paris.fr

Accepted for publication 4 June 2002

References

- 1 **Giuffrè G**, Palumbo C, Randazzo-Papa G. Optic atrophy and central retinal vein occlusion. *Br J Ophthalmol* 1993;**77**:774–7.
- 2 **Slusher MM**, Tyler ME. Chorioretinal vascular anastomoses. *Am J Ophthalmol* 1980;**90**:217–22.

Loss of myelinated retinal nerve fibres in diabetic retinopathy

Myelinated retinal nerve fibres usually remain unchanged but loss of myelin can occur either from primary demyelination (for example, optic neuritis) or secondary to retinal ganglion cell damage. We present a case of extensive loss of myelinated retinal nerve fibres as a result of progressive diabetic retinopathy. To our knowledge, this is a rare observation.

Case report

A 64 year old African-American woman with diabetes mellitus for 11 years, hypertension for 5 years, and hypercholesterolaemia presented, after being lost to follow up, with progressive blurred vision in both eyes. There was

no history of glaucoma, laser treatment, or any other significant medical or neurological disease. Visual acuity was counting fingers in the right eye and 20/400 in the left eye. The pupillary examination, gonioscopy, and applanation tonometry were normal. A moderate nuclear sclerosis was present. Funduscopy examination revealed severe proliferative diabetic retinopathy with vitreous haemorrhages in both eyes. The left eye had peripapillary myelinated retinal nerve fibres (Fig 1) with partially cicatricial retinal neovascularisation and low lying tractional retinal detachments along the superotemporal and inferotemporal arcades. There was diffuse macular oedema with cystoid changes. Fundus photographs taken 6 years earlier revealed severe non-proliferative diabetic retinopathy with macular oedema in both eyes and much more extensive peripapillary myelinated nerve fibres of the left eye (Fig 2).

The area of myelinated retinal nerve fibres had markedly decreased allowing visualisation of the previously obscured retinal vessels

Figure 1 Proliferative diabetic retinopathy, with partially cicatricial retinal neovascularisation and low lying tractional retinal detachments along the superotemporal and inferotemporal arcades. Marked reduction of peripapillary myelinated retinal nerve.

Figure 2 Non-proliferative diabetic retinopathy of the left eye with extensive peripapillary myelinated nerve fibres.

and optic disc margin. The loss of myelinated retinal nerve fibres was more pronounced at the superior and inferior disc margins corresponding to the areas of tractional retinal detachment.

Comment

Myelinated retinal nerve fibres are usually benign, developmental abnormalities found on routine examination. They occur when myelination of the optic nerve continues beyond the lamina cribrosa to involve the retinal nerve fibres. On funduscopy, they typically appear as a solitary white or grey-white striated patch which follows the nerve fibre layer. In a series of 3968 consecutive necropsies the incidence of myelinated retinal nerve fibres was found to be 0.98%.¹

Myelinated retinal nerve fibres usually remain unchanged. Loss of myelin can occur either from primary demyelination—for example, in optic neuritis² or secondary to retinal ganglion cell damage. The latter can be caused by ischaemia, inflammation, degeneration, or compression anywhere along the path of the retinal ganglion cell from the inner retinal layer to the lateral geniculate body. Reported examples involving inner retinal ischaemia as a cause of myelinated retinal nerve fibre loss include branch retinal artery occlusion³ and central retinal artery occlusion.⁴ In diabetic retinopathy, ischaemic changes occur in the inner retina, leading to damage to the ganglion cell and atrophy of the nerve fibre layer. This is the mechanism responsible for the loss of myelinated retinal nerve fibres in our patient. Tractional retinal detachment, usually a late complication of diabetic retinopathy, most likely contributed to the atrophy. Ischaemic damage to the retinal nerve fibres is common in early diabetic retinopathy. Chihara *et al.*,⁵ using retinal nerve fibre layer photographs, found retinal nerve fibre layer defects to be common in eyes with diabetic retinopathy. We report the observation that inner retinal ischaemia secondary to diabetic retinopathy can result in the loss of myelin in the of myelinated retinal nerve fibres.

R C. Gentile, L Torqueti-Costa, A Bertolucci

Vitreo-Retinal Service, The New York Eye and Ear Infirmary, New York, 10003 NY, and the New York Medical College, Valhalla, 10595 NY, USA

Correspondence to: Mr Ronald C Gentile; rgentile@nyee.edu

Accepted for publication 4 June 2002

References

- 1 **Straatsma BR**, Foos RY, Heckenlively JR, *et al.* Myelinated retinal nerve fibers. *Am J Ophthalmol* 1981;**91**:25–38.
- 2 **Sharpe JA**, Sanders MD. Atrophy of myelinated nerve fibers in the retina in optic neuritis. *Br J Ophthalmol* 1975;**59**:229–32.
- 3 **Tecih SA**. Disappearance of myelinated retinal nerve fibers after a branch retinal artery occlusion. *Am J Ophthalmol* 1987;**103**:835–7.
- 4 **Bachmann R**. Schwund markhaltiger Nervenfasern in der Netzhaut nach Embolie der Art. Centralis retinae. *Albrecht von Graefes Arch. Ophthalmol* 1922;**107**:10.
- 5 **Chihara E**, Matsuo T, Ogura Y, *et al.* Retinal nerve fiber layer defect as an early manifestation of diabetic retinopathy. *Ophthalmology* 1993;**100**:1147–51.

Microscopic fragmentation of ophthalmic surgical sponge spears used for delivery of antiproliferative agents in glaucoma filtering surgery

Trabeculectomy remains the standard surgical glaucoma procedure against which other procedures are measured. The incidence of failure of trabeculectomy in higher risk cases can be reduced with the use of the adjuvant antiproliferative agents 5-fluorouracil and mitomycin C.^{1,2} The standard method of delivery of these adjuvant agents to the surgical site is via several small pieces of microsurgical sponge spear.

A recent change in our practice in augmented trabeculectomy has been to use cut pieces of polyvinyl alcohol (PVA) sponge, instead of cut pieces of cellulose sponge for antiproliferative agent delivery to the surgical site. This change in practice was because the PVA sponges seemed to be less friable after cutting than the cellulose sponges, and less likely to leave remnants behind after removal. We carried out this study to try to confirm these suspicions. In addition, we wanted to assess whether residual microfragments of different sponge surgical spears routinely used for blood and fluid absorption during glaucoma drainage surgery are left behind.

Materials, methods, results

Four different microsurgical sponge spears were assessed: two brands of cellulose ophthalmic spears (Cellulose Spears, Eyetec Ophthalmic Products, Altomed Ltd, UK and Visi-spear Eye Sponge, Visitec, Becton Dickinson and Company, USA), one brand of PVA ophthalmic spear (PVA Spears, Eyetec Ophthalmic Products, Altomed Ltd, UK), and one brand of reprocessed PVA ophthalmic LASIK spear (Lasik Spear Classic, Eyetec Ophthalmic Products, Altomed Ltd, UK).

Each type of sponge spear was cut with sharp scissors into small fragments, which were then soaked in 5-fluorouracil 25 mg/ml or mitomycin C 0.2 mg/ml. Fresh cadaveric pig eyes were prepared with a fornix based conjunctival flap as if for trabeculectomy. In each eye, four antiproliferative agent soaked sponge fragments were placed with non-toothed forceps for 4 minutes on the scleral bed beneath the fornix based conjunctival flap. The sponges were removed with non-toothed forceps, and the subconjunctival space was irrigated with 10 ml balanced salt solution. The sclera and conjunctiva were fixed and processed for microscopic examination.

We also assessed whether the whole microsurgical sponge spears used for intraoperative blood and fluid absorption leave behind any microfragments. The same four types of sponge spear were each used to wipe away balanced salt solution on fresh cadaveric pig sclera, prepared with half thickness scleral incisions to simulate initial creation of a scleral flap in glaucoma drainage surgery. The sclera was then fixed and processed for microscopic examination.

Before processing the cadaveric pig eyes, it was found that cellulose sponge was identifiable by microscopy by its birefringence in plain polarised light. PVA and reprocessed PVA were found to stain with periodic acid Schiff (PAS) stain (Fig 1). The observer of the microscopy slides was blind as to which sponge spear had been used in each case.

In four repeated experiments, cut pieces of both brands of cellulose microsurgical sponge

Figure 1 Microscopic appearance of microsurgical sponge. (A) Cellulose, haematoxylin and eosin. (B) Cellulose, birefringence in plain polarised light. (C) Polyvinyl alcohol (PVA), haematoxylin and eosin. (D) PVA, periodic acid Schiff (PAS). (E) Reprocessed PVA, haematoxylin and eosin. (F) Reprocessed PVA, PAS. Bar = 1 mm.

Figure 2 Microscopy of the conjunctiva, sclera interface. (A) Visi-spear Eye Sponge (cellulose) + mitomycin C, haematoxylin and eosin. (B) Visi-spear Eye Sponge + mitomycin C, plain polarised light. (C) Cellulose Spear, Eyetec + 5-fluorouracil, haematoxylin and eosin. (D) Cellulose Spear, Eyetec + 5-fluorouracil, plain polarised light. Bar = 1 mm.

Table 1 Microfragments of surgical sponge spears left at the surgical site

	Sponge absorption		
	Sponge pieces + 5-FU	Sponge pieces + MMC	Whole fluid
Cellulose spears, Eyetec	+	+	–
Visispear eye sponge, Visitec (cellulose)	+	+	–
PVA spears, Eyetec	–	–	–
Lasik Spear Classic, Eyetec (reprocessed PVA)	–	–	–

spears left behind microfragments at the conjunctiva-sclera interface, when soaked with 5-fluorouracil or with mitomycin C (Fig 2). The PVA ophthalmic spears and the reprocessed PVA ophthalmic spears did not leave behind any microfragments, whether soaked with 5-fluorouracil or mitomycin C.

When whole sponge spears were used for fluid absorption, none of the four types of microsurgical sponge spear left any microfragments behind on the scleral bed. Full results are shown in Table 1.

Comment

This study demonstrates that in cadaveric porcine eyes cut pieces of cellulose sponge used for antiproliferative agent delivery in glaucoma filtering surgery leave behind microfragments at the conjunctival-scleral interface. Cut pieces of PVA sponge or reprocessed PVA sponge do not leave behind microfragments. This is in keeping with the marketing of PVA spears as the ideal microsurgical sponge spear for use in laser in situ keratomileusis (LASIK): when used for fluid absorption at the corneal stromal interface in LASIK, PVA is less likely to fragment and leave interface deposits than cellulose.

Antiproliferative agent delivery to the surgical site in trabeculectomy aims to reduce fibrosis, thereby promoting a functioning filtering bleb. Retained microfragments of antiproliferative soaked cellulose sponge at the surgical site may adversely affect the surgical outcome. Cellulose sponge can be regarded as a slowly degradable material. The time needed for the total disappearance of cellulose sponge from subcutaneous tissue in rats is longer than 60 weeks.³ Cellulose is also known to be capable of initiating a foreign body reaction: in the peritoneal cavity, retained cellulose can lead to a foreign body granuloma and intestinal obstruction.⁴ Cellulose microfragments retained in the subconjunctival space are therefore a risk to good bleb formation, and likely to be present throughout the important first weeks of healing following trabeculectomy.

Slowly degrading microfragments of foreign body may increase the risk of infection, including blebitis. In addition, retained microfragments soaked in antiproliferative agent will increase the dose of antiproliferative to the area, which in turn increases the risk of adverse effects, such as thin avascular blebs with mitomycin C. The elimination half life for intravenous 5-fluorouracil and mitomycin C is 20 hours and 50 minutes respectively; it is probably longer than this outside the vascular system, in the subconjunctival space. Larger retained sponge fragments soaked in antiproliferative can lead to necrosis of the overlying conjunctiva.⁵

Uncut whole sponges used for fluid absorption on the scleral bed did not leave behind microfragments on the sclera, whether made of cellulose or PVA. Therefore it may be the

cutting of cellulose sponges, to provide smaller fragments for antiproliferative agent delivery, that is responsible for leaving friable cellulose edges.

Experiments using cadaveric porcine eyes might not accurately simulate the human in vivo situation. However, if the simulation is accurate, whole cellulose microsurgical spears appear to be safe for use in blood and fluid absorption in glaucoma surgery, whereas cut pieces of cellulose sponge used for antiproliferative agent delivery leave behind microfragments. We conclude that PVA microsurgical sponge is a safer vehicle for antiproliferative agent delivery in trabeculectomy.

T R G Poole, I H Gillespie,

Royal Eye Unit, Kingston Hospital, Galsworthy Road, Kingston upon Thames, Surrey, KT2 7QB, UK

G Knee, J Whitworth

Department of Histopathology, Kingston Hospital

Correspondence to: Mr T R G Poole; trgp@fish.co.uk

Accepted for publication 12 June 2002

References

- 1 Mora JS, Nguyen N, Iwach AG, et al. Trabeculectomy with intraoperative sponge 5-fluorouracil. *Ophthalmology* 1996;**103**:963–70.
- 2 Palmer SS. Mitomycin as adjunct chemotherapy with trabeculectomy. *Ophthalmology* 1991;**98**:317.
- 3 Martson M, Viljanto J, Hurme T, et al. Is cellulose sponge degradable or stable as implantation material? An in vivo subcutaneous study in the rat. *Biomaterials* 1999;**20**:1989–95.
- 4 Tinker MA, Teicher I, Burdman D. Cellulose granulomas and their relationship to intestinal obstruction. *Am J Surg* 1977;**133**:134–9.
- 5 Shin DH, Tsai CS, Kupin TH, et al. Retained cellulose sponge after trabeculectomy with adjunctive subconjunctival mitomycin C. *Am J Ophthalmol* 1994;**118**:111–12.

Vision threatening vitreous haemorrhage after internal limiting membrane peeling in macular surgeries

Indocyanine green (ICG) dye has been used to stain the retinal internal limiting membrane (ILM) and facilitate its removal in macular hole and epiretinal membrane (ERM) surgeries.^{1,2} In our previous study, removal of ICG stained ILM around idiopathic macular hole was confirmed with histology.¹ Here we report two (3.6%) cases of vision threatening vitreous haemorrhage out of 55 prospective consecutive cases operated by one of the authors (AKHK) with ICG assisted ILM removal in macular hole and ERM surgeries.

Case 1

A 73 year old woman with essential hypertension presented with moderate cataract and

a chronic stage 4 macular hole of 500 µm in the right eye; and cataract and stage 2 macular hole of 250 µm in the left eye. Best corrected Snellen visual acuity (BCVA) was hand movements and 6/36 in the right and left eye, respectively. Standard pars plana vitrectomy (PPV), induction of posterior hyaloid detachment, and removal of ICG stained ILM around the macular hole up to the temporal arcade vessels and optic disc margin was performed in the left eye. This was followed by a two stage fluid-air exchange and finally 12% perfluoropropane as internal tamponade. The perioperative course was uneventful. On the sixth postoperative day, the patient returned after she had bumped her head gently against a table. Significant vitreous haemorrhage was found in the left eye. The intraocular pressure was normal and ultrasonography revealed no retinal detachment. Two months postoperatively, the vitreous haemorrhage persisted and an uneventful external fluid-air exchange was then performed. Three months postoperatively, her BCVA was 6/36 with a closed macular hole and significant decrease of central scotoma in the left eye.

Case 2

A 65 year old man with essential hypertension presented with mild cataract and ERM with disturbing metamorphopsia in the left eye. BCVA was 6/12 and 6/18 in the right and left eye, respectively. PPV and removal of ERM with ICG stained ILM was performed. The perioperative course was uneventful. On the sixth postoperative day, the patient returned with a sudden drop in vision in the left eye. Significant vitreous haemorrhage was found. Ultrasonography revealed no retinal detachment. On the 12th postoperative day, a haemolytic glaucoma occurred with an intraocular pressure of 55 mm Hg, which was successfully controlled by a combination of systemic and topical antiglaucomatous drugs. Three weeks postoperatively, the vitreous haemorrhage resolved almost completely. The intraocular pressure was normal without drugs. Three months postoperatively, BCVA was 6/12 with no recurrence of ERM and significant improvement of metamorphopsia in the left eye.

Comment

Recently, suspected complications associated with ILM peeling, with or without ICG, have been reported.^{3,4} These included small asymptomatic scotomas and retinal tissue detected with ILM under electron microscopy. Although minimal superficial retinal haemorrhages are commonly encountered as ILM is peeled, they are usually self limiting and harmless. However, Brooks reported that three (2.5%) eyes developed postoperative hyphaema that required repeat vitrectomy or anterior chamber washout.⁵ We report two (3.6%) cases of vision threatening vitreous haemorrhage out of a prospective consecutive series of 55 cases operated by one surgeon with ICG assisted ILM removal. We suspect that ILM peeling may expose the already compromised superficial retinal vessels in hypertensive patients, and trauma may precipitate a significant vitreous haemorrhage. Limiting the areas of ILM peeling, avoidance of trauma, and adequate control of essential hypertension may decrease the chance of such complication.

Financial interest: Nil.
Financial support: Nil.

A K H Kwok, D Y L Leung, C Hon,
D S C Lam

Department of Ophthalmology and Visual Sciences,
The Chinese University of Hong Kong, Hong Kong
Eye Hospital, Kowloon, Hong Kong, People's
Republic of China

A K H Kwok

Department of Ophthalmology, Queen Mary
Hospital, Hong Kong, People's Republic of China

Correspondence to: Dr Alvin K H Kwok,
Department of Ophthalmology and Visual Sciences,
The Chinese University of Hong Kong, Hong Kong
Eye Hospital, 147K, Argyle Street, Kowloon, Hong
Kong; kwokkh@ha.org.hk

Accepted for publication 10 June 2002

References

- 1 Kwok AKH, Li WW, Pang CP, *et al.* Indocyanine green staining and removal of internal limiting membrane in macular hole surgery: histology and outcome. *Am J Ophthalmol* 2001;**132**:178–83.
- 2 Okamoto N, Kumagai K, Demizu S, *et al.* Retinal thickness analysis after the epiretinal membrane surgery with internal limiting membrane peeling. [ARVO Abstract 3916] *Invest Ophthalmol Vis Sci* 2001;**42**:S729.
- 3 Gandorfer A, Haritoglou C, Gass CA, *et al.* Indocyanine green-assisted peeling of the internal limiting membrane may cause retinal damage. *Am J Ophthalmol* 2001;**132**:431–3.
- 4 Haritoglou C, Gass CA, Schaumberger M, *et al.* Macular changes after peeling of the internal limiting membrane in macular hole surgery. *Am J Ophthalmol* 2001;**132**:363–8.
- 5 Brooks HL Jr. Macular hole surgery with and without internal limiting membrane peeling. *Ophthalmology* 2000;**107**:1939–49.

Liposarcoma of the orbit presenting as an enlarged medial rectus muscle on CT scan

Primary orbital liposarcoma is extremely rare in the orbit. Only a few published cases have included imaging studies, showing findings varying from well defined, homogeneous lesions of soft tissue density to heterogeneous masses containing fat.^{1,2} We report one patient who presented with painless proptosis and double vision and had an enlargement of the medial rectus muscle on computed tomography (CT) as the sole initial imaging finding.

Case report

A 75 year old man presented with a 3 month history of painless diplopia and protrusion of the left eye. His medical history revealed only diabetes mellitus. On ophthalmic examination his visual acuity was 6/6 in the right eye and 6/9 in the left eye. There was a reddish tumoral growth in the medial canthus of the left eye, right above the insertion of the

medial rectus muscle below the conjunctiva. The left eye as dislocated laterally and anteriorly, with 2 mm of proptosis, limitation of adduction, elevation, and depression.

A CT scan was obtained and revealed marked enlargement of the medial rectus muscle throughout its extension, with enhancement after intravenous contrast administration (Fig 1). Extensive laboratory investigation including thyroid hormones and TSH was normal except for diabetes. A trial of oral prednisone (80 mg/day) was introduced for 1 week without any improvement in his condition and therefore a transconjunctival biopsy of the lesion was performed. It revealed a pleomorphic liposarcoma and a radical tumour removal was indicated. The patient was reluctant to accept it and returned only 2 months later when there was marked enlargement of the tumour. A repeat CT scan revealed that the tumour extended to the orbital fat and was now a heterogeneous lesion with central hypodense areas circumscribed by hyperdense, contrast enhancing areas (Fig 2).

The patient underwent orbital exenteration followed by skin graft of the orbital cavity and postoperative orbital irradiation. There was complete removal of the tumour that was restricted to the orbit. The patient remained free of tumour for the following 6 years, when he died as a result of systemic complications after a femur fracture.

Comment

Despite the large amount of adipose tissue in the orbit, primary orbital liposarcomas are extremely rare, with only 27 cases previously reported.^{1–7} Metastatic orbital liposarcomas are also extremely rare with only a few cases documented in the literature.⁸ When liposarcoma occur in the orbit there is no specific pattern of involvement and the tumour presents marked diversity of clinical presentations. Our patient presented initially with a tumour restricted to the medial rectus muscle with a radiological appearance very similar to the metastatic liposarcoma reported by Fezza and Sinard.⁸ Contrary to their case, however, our patient did not have any history of systemic disease and did not develop tumour elsewhere in the body in a 6 year follow up period. Although preferential involvement of one extraocular muscle has been documented,¹ to our knowledge none of the previously described cases of primary orbital liposarcoma was restricted to the extraocular muscle as in our case.

Although the differential diagnosis of extraocular muscle enlargement is extensive and includes Graves' orbitopathy, myositis, carotid cavernous fistula, lymphoma, metastatic tumours, etc, our case shows that physi-

cians should include a liposarcoma in differential diagnosis of patients in which the clinical and laboratory findings are not in accordance with other more common causes of extraocular muscle enlargement.

M L R Monteiro

Division of Ophthalmology, Hospital das Clínicas of
the University of São Paulo Medical School, São
Paulo, Brazil

Correspondence to: mlrmonteiro@terra.com.br

Accepted for publication 19 June 2002

References

- 1 McNab AA, Moseley I. Primary orbital liposarcoma: clinical and computed tomographic features. *Br J Ophthalmol* 1990;**74**:437–9.
- 2 Jakobiec FA, Rini F, Char D, *et al.* Primary liposarcoma of the orbit. Problems in the diagnosis and management of five cases. *Ophthalmology* 1989;**96**:180–91.
- 3 Naeser P, Moström U. Liposarcoma of the orbit: a clinicopathological case report. *Br J Ophthalmol* 1982;**66**:190–3.
- 4 Lane CM, Wright JE, Garner A. Primary myxoid liposarcoma of the orbit. *Br J Ophthalmol* 1988;**72**:912–17.
- 5 Favrot SR, Ridley MB, Older JJ, *et al.* Orbital liposarcoma. *Otolaryngol Head Neck Surg* 1994;**111**:111–15.
- 6 Cockerham KP, Kennerdell JS, Celin SE, *et al.* Liposarcoma of the orbit: a management challenge. *Ophthalm Plast Reconstr Surg* 1998;**14**:370–4.
- 7 Wagle AM, Biswas J, Subramaniam N, *et al.* Primary liposarcoma of the orbit: a clinicopathological study. *Orbit* 1999;**18**:33–6.
- 8 Fezza J, Sinard J. Metastatic liposarcoma to the orbit. *Am J Ophthalmol* 1996;**123**:271–2.

Concentration of intravitreally injected triamcinolone acetonide in intraocular silicone oil

For decades, corticosteroids have been known to reduce inflammation and, depending on their concentration, to suppress proliferation of cells. Applied either locally or systemically, steroids have consequently been used for treatment of various ocular diseases. Often, however, the intraocular concentrations of cortisone were not sufficiently high, or the systemic side effects were too pronounced, to effectively treat the ocular disorder. Taking into account that the eye comprises only 0.01% of the whole body volume, and considering that for achieving high concentrations of a drug at its site of action it is best to apply it directly into the region of requested action, Machemer and other researchers studied the possibility of injecting cortisone directly into the eye.¹ Clinical studies have correspondingly revealed that a single intraocular injection of triamcinolone acetonide may be a therapeutic option as adjunctive treatment of exudative age related macular degeneration, diabetic cystoid macular oedema, and proliferative diabetic retinopathy.^{2–5}

It has been unknown so far, how long after a single intravitreal injection, clinically detectable concentrations of triamcinolone acetonide are available in the eye. Ophthalmoscopic findings of patients who received an intravitreal injection of triamcinolone acetonide suggest that triamcinolone acetonide crystals remain visible in the eye up to about 6 months after the injection.³ The aim of this study was, therefore, to assess the concentration of triamcinolone acetonide in silicone oil samples removed from patients who had previously undergone pars plana vitrectomy with silicone oil endotamponade.

Figure 1 Marked enlargement of the left medial rectus muscle on CT scan.

Figure 2 CT scan showing heterogeneous lesion with central hypodense areas circumscribed by hyperdense, contrast enhancing areas.

Case report

The study included three patients (one woman, two men) with a mean age of 57.7 (SD 5.4) years. They had undergone pars plana vitrectomy with silicone oil endotamponade as treatment of proliferative vitreoretinopathy ($n=2$) or proliferative diabetic vitreoretinopathy ($n=1$). At the end of surgery, 25 mg of triamcinolone acetonide were injected into the silicone oil bubble. Silicone oil was removed 2, 5, and 8 months, respectively, after the instillation, and the concentrations of triamcinolone acetonide were determined.

The concentration of triamcinolone acetonide was 3 µg/kg silicone oil in the silicone oil sample removed from the eye which had undergone pars plana vitrectomy 4 months before the oil removal, and in which the retina remained attached after the release of silicone oil. Concentration of triamcinolone acetonide was 61 µg/kg silicone oil in the sample removed 7 months after the instillation into the eye in which the retina was attached before the silicone oil removal, in which, however, the retina re-detached within 1 week after release of the oil. In the sample which was removed 8 months after instillation, concentration of triamcinolone acetonide was 11 µg/kg silicone oil. In that eye, the retina was partially detached before the removal of the silicone oil, and the eye underwent a second pars plana vitrectomy.

Comment

The results suggest that detectable concentrations of triamcinolone acetonide can be found in intraocular silicone oil samples up to 8 months after its instillation. Future studies may evaluate which factors, besides the time interval after its injection, may be responsible for the varying concentration of triamcinolone acetonide.

Proprietary interest: none.

J B Jonas

Department of Ophthalmology, Faculty for Clinical Medicine Mannheim, Ruprecht-Karls-University Heidelberg, Germany

Correspondence to: Universitäts-Augenklinik, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany; Jost.Jonas@augen.ma.uni-heidelberg.de

Accepted for publication 26 June 2002

References

- 1 Macherer R, Sugita G, Tano Y. Treatment of intraocular proliferations with intravitreal steroids. *Trans Am Ophthalmol Soc* 1979;77:171-80.
- 2 Macherer R. Five cases in which a depot steroid (hydrocortisone acetate and methylprednisolone acetate) was injected into the eye. *Retina* 1996;16:166-7.
- 3 Challa JK, Gillies MC, Penfold PL, et al. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. *Aust N Z J Ophthalmol* 1998;26:277-81.
- 4 Danis RP, Ciulla TA, Pratt LM, et al. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. *Retina* 2000;20:244-50.
- 5 Jonas JB, Hayler JK, Söfker A, et al. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. *Am J Ophthalmol* 2001;131:468-71.

Focal limbal stem cell deficiency corresponding to an iris coloboma

When the stem cells population is destroyed or their supporting stromal environment is

dysfunctional, limbal stem cell deficiency (LSCD) manifests. Clinically, LSCD carries the hallmark of conjunctivalisation—that is, the corneal surface is covered by ingrowing conjunctival epithelium containing goblet cells. Conjunctivalisation is invariably associated with the destruction of the basement membrane, emergence of superficial neovascularisation, scarring, and diminished visual acuity.¹⁻⁴

Corneal diseases associated with LSCD can be subdivided into two major categories.⁴ In the first category, limbal epithelial stem cells have been previously destroyed by a known or recognisable insult. The second category is characterised by a gradual loss of the stem cell population without a known or identifiable factor. In this second category, the limbal stromal environment, so called niche, is presumably affected progressively by different aetiologies including aniridia.⁵ Although iris coloboma has been noted to be associated with corneal surface abnormalities,^{6,7} no report appears to confirm if this developmental abnormality is also associated with LSCD. Here we report one such case, which manifested focal LSCD in the same area of iris coloboma.

Figure 1 (A) Slit lamp examination of the right eye of a 51 year old man showing a central corneal epithelial defect and peripheral superficial corneal vascularisation located in the inferonasal quadrant. (B) An irregular epithelium in a migratory pattern noted in the affected corneal quadrant, and peripheral late fluorescein staining in the same area. (C) Impression cytology confirming the presence of conjunctival epithelial cells and goblet cells, shown by white arrows.

Case report

In 1988, a 38 year old male patient was referred for evaluation of a peripheral vascularisation in his right eye and a persistent epithelial defect in the left eye after two previous failed penetrating keratoplasties. At that time, an inferonasal iris coloboma associated with regional peripheral superficial vascularisation and mild corneal haze was noted in the right eye, which also had a past history of amblyopia with a best corrected visual acuity of 20/200. Impression cytology performed then did not show any evidence of conjunctivalisation in the right eye. The left eye has received three additional penetrating keratoplasties (two for inadvertent blunt trauma leading to wound dehiscence) and with a contact lens he could see 20/30.

In 2002, he presented with a complaint of progressive foreign body sensation and redness in his right eye. Slit lamp examination revealed a central corneal epithelial defect and peripheral superficial corneal vascularisation located in the same quadrant where an iris coloboma was present (Fig 1A). An irregular epithelium in a migratory pattern was noted in the affected corneal quadrant, where late fluorescein staining was also found (Fig 1B). Repeat impression cytology confirmed the presence of conjunctival epithelial cells and goblet cells on the peripheral cornea of this region, supporting the diagnosis of focal LSCD (Fig 1C).

Comment

Previously, Soong and Raizman⁶ reported four patients with iris coloboma that were accompanied by corneal changes. Here, for the first time, we demonstrate that these corneal changes may represent or eventually evolve into a state of LSCD by the use of impression cytology disclosing the hallmark of conjunctivalisation.⁴ These abnormal epithelial changes were associated with corneal epithelial erosion adjacent to an irregular migratory epithelium with late fluorescein staining, and superficial peripheral corneal vascularisation. Other known aetiologies for partial limbal deficiencies were excluded in this patient. The strong anatomical correlation of focal LSCD in the region of iris coloboma resembles what has been reported in patients with aniridia in which total LSCD is found invariably in eyes lacking the development of the entire iris.^{4,5} In aniridia, these abnormal corneal changes develop as early as the first decade of age and progressed rapidly to total conjunctivalisation.⁵ Mutations in the *PAX6* gene are associated with a wide range of ocular abnormalities including anophthalmos, aniridia, and various anterior segments anomalies with peripheral vascularisation.⁹ A reduction of *PAX6* activity in heterozygotes for *PAX6* mutation results in aniridia in humans and nanophthalmos in the knockout mice.¹⁰ We thus speculate that a less severe alteration of *PAX6* might have a role in the ocular surface changes observed in coloboma. Such a similarity between iris coloboma and aniridia prompts us to speculate that these two diseases might share the same underlying pathogenesis. This interpretation strengthens our hypothesis that deficiency in the iris development is accompanied by the abnormality of the limbal stroma that is vital to the support of limbal epithelial stem cells. Future studies dissecting into this correlation will help unravel the secrecy concerning the regulation of limbal epithelial stem cells.

Proprietary interest: None.

E M Espana, VK Raju, S C G Tseng

Ocular Surface Center and Ocular Surface
Research and Education Foundation, Miami,
Florida, USA

Correspondence to: Scheffer C G Tseng, MD, PhD,
Ocular Surface Center and Ocular Surface
Research and Education Foundation, 8780 SW 92
Street, Suite 203, Miami, FL 33176, USA;
stseng@ocularsurface.com

Accepted for publication 18 June 2002

References

- 1 **Dua HS**, Forrester JV. The corneoscleral limbus in human corneal epithelial wound healing. *Am J Ophthalmol* 1990;**110**:646–56.
- 2 **Huang AJW**, Tseng SCG. Corneal epithelial wound healing in the absence of limbal epithelium. *Invest Ophthalmol Vis Sci* 1991;**32**:96–105.
- 3 **Chen JJY**, Tseng SCG. Abnormal corneal epithelial wound healing in partial thickness removal of limbal epithelium. *Invest Ophthalmol Vis Sci* 1991;**32**:2219–33.
- 4 **Puangricharn V**, Tseng SCG. Cytologic evidence of corneal diseases with limbal stem cell deficiency. *Ophthalmology* 1995;**102**:1476–85.
- 5 **Nishida K**, Kinoshita S, Ohashi Y, *et al*. Ocular surface abnormalities in aniridia. *Am J Ophthalmol* 1995;**120**:368–75.
- 6 **Soong HK**, Raizman MB. Corneal changes in familial iris coloboma. *Ophthalmology* 1986;**93**:335–9.
- 7 **Hornby SJ**, Adolph S, Gilbert CE, *et al*. Visual acuity in children with coloboma: clinical features and a new phenotypic classification system. *Ophthalmology* 2000;**107**:511–20.
- 8 **Margo CE**. Congenital aniridia: a histopathologic study of the anterior segment in children. *J Pediatr Ophthalmol* 1983;**20**:192–8.
- 9 **Ashery-Padan R**, Gruss P. Pax6 lights-up the way for eye development. *Curr Opin Cell Biol* 2001;**13**:706–14.
- 10 **Marquardt T**, Ashery-Padan R, Andrejewski N, *et al*. Pax6 is required for the multipotent state of retinal progenitor cells. *Cell* 2001;**105**:43–55.

Novel nonsense mutation (Tyr44stop) of the Norrie disease gene in a Japanese family

Norrie disease (ND) is an X linked genetic disorder causing bilateral blindness in early infancy because of severely dysplastic retinas. The major disease phenotype is a retrolental mass caused by undifferentiated, proliferated vitreous and retina, accompanied by maldeveloped anterior segment, leading to atrophy of the eyeball. A certain number of patients show psychomotor retardation or hearing impairment as part of a multisystem disorder.¹ After the identification of the gene for ND, various types of pathological mutations have been documented in different ethnic groups.^{2,3} Phenotype-genotype evaluation has clarified that a mutation in the ND gene may also be responsible for a separate clinical entity, exudative vitreoretinopathy, retinopathy of prematurity, or unclassified retinal dysplasia.^{4,5} The clinical distinction between sporadic ND and bilateral persistent hyperplastic primary vitreous (PHPV) can be difficult.^{6,7} We report a novel truncating mutation of the ND gene in a Japanese family, in whom the proband was initially diagnosed with a sporadic form of PHPV.

Case report

The proband (patient 1) was the first son of non-consanguineous parents. He was born in 1993 with full term uneventful delivery and

his mother noticed bilateral leucocoria 2 weeks after birth. An ophthalmologist suggested a severe case of PHPV in both eyes, and the patient underwent vitreous surgery on the right eye at 4 months of age because of the haemorrhage behind the lens. The patient was referred to our hospital at 15 months of age for further clinical distinction and prognostic counselling of his ocular conditions. On examination, he had normal psychomotor development and normal hearing ability. Pupils were not responsive to light and the visual acuity was no light perception in both eyes. The corneal diameter was 4 mm right eye and 9 mm left eye and band-shaped keratopathy was present in both eyes. A vascularised retrolental fibrous mass was barely visible behind the hazy lens accompanied by posterior synechiae in each eye. Ultrasonography showed a funnel-shaped retrolental mass in each eye. Scotopic electroretinograms were non-recordable. Visual evoked potential measurements revealed tentative P 100 wave forms in both eyes. Eyeballs showed a gradual shrinkage in subsequent follow up studies to 7 years of age.

The parents and their second son were healthy with normal vision. The other family members had lived long in the Osaka area, Japan. According to the statements from the parents, the family members had normal vision. At this phase, patient 1 was thus diagnosed as a sporadic, severe form of bilateral PHPV.

In 2000, the third son (patient 2) was born at full term with uneventful delivery. The parents noticed bilateral leucocoria at birth. On examination at 6 days of age, the pupils were not responsive to light. Corneal diameters were 9 mm in both eyes. Each eye had a clear media but showed a vascularised retrolental whitish-yellow mass with ectropion uveas and posterior synechiae. Ultrasonography showed a funnel-shaped retrolental mass in each eye with axial lengths of 16 mm in both eyes. Magnetic resonance imaging revealed a more detailed feature of the retrolental masses (Fig 1). Results of electroretinograms and visual evoked potential measurements were similar to those of patient 1. During the

Figure 1 Ocular findings in patient 2. (A) R = right eye; L = left eye. Ultrasonography suggests a funnel-shaped retrolental mass in each eye with shortened axial lengths. (B) T1 weighted magnetic resonance imaging clarifies microphthalmic eyes, retrolental masses, abnormal lenses, and enhancement in the anterior chambers due to elongated ciliary processes.

subsequent follow up period, the eyeballs of patient 2 showed a gradual shrinkage and he remained unremarkable in neurological or otological studies.

We obtained peripheral blood with informed consent and analysed DNA samples of patient 2, his mother, and 100 normal controls, for mutations in the ND gene. One female and three male sporadic patients with bilateral PHPV were examined simultaneously as pathological controls. Patient 1 was not accessible for the molecular genetic examination. The coding exons of the ND gene were amplified according to the published data.⁸ Sense and antisense nucleotide sequences of the amplicons were directly determined by dye terminator autocyclus sequencing. Patient 2 had a hemizygous mutation at Tyr 44 of the ND gene—namely, an insertion of adenine (TAT to TAAT) that creates a premature terminator (Ochre) to predict elimination of the subsequent amino acids of the ND protein (Fig 2). His mother had the normal and mutant types of the gene, which was expected for heterozygotes of the disease. On the other hand, four patients with bilateral PHPV and 100 normal controls showed only wild type sequences of the relevant gene.

Comment

In Japanese families, ND gene mutations have been identified at the initiation codon (Met to Val) and codon 95 (Cys to Arg).⁹ This Japanese family shows a novel nonsense mutation (Tyr44stop) of the ND gene in a manner expected for an X linked genetic disease. This is the fourth Japanese family with ND in whom mutations of the ND gene were identified. We are unaware of previous reports of this mutation and could find no reference to it in a computerised search utilising Online Mendelian Inheritance in Man (OMIM) or the Cardiff Human Gene Mutation Database (HGMD).^{2,3} Among 60 types of ND gene mutations in the literature, seven nonsense mutations are located at Ser 29, Ser 57, Ser 73, Arg 109, Cys 110, Cys 126, and Cys 128, with typical clinical features of ND. In the manner similar to these mutations, Tyr44stop in the present report presumably eliminates subsequent 90 amino acid peptide when the gene is expressed. It is therefore likely that the present mutation has a strong effect leading to the ND phenotype.

The proband (patient 1) in the present family had been diagnosed as a sporadic form

Figure 2 Sequencing results of the ND gene. Patient 2 has a hemizygous mutation at codon 44 of the ND gene—namely, an insertion of adenine (TAT to TAAT, arrow) that creates a premature terminator (Ochre) to predict elimination of the subsequent amino acid of the ND protein.

of bilateral PHPV until the third male offspring (patient 2) was born blind. Magnetic resonance imaging may be superior in demonstrating the retrolental masses to computed tomography imaging or ultrasonography.¹⁰ Magnetic resonance imaging in patient 2 clarified a detailed feature of the intraocular abnormalities including retrolental masses, abnormal lenses, elongated ciliary processes, and microphthalmic eyes. This type of morphological appearance would not be inconsistent with PHPV. It is clinically difficult to distinguish ND from PHPV with undefined aetiology especially in sporadic cases and the diagnostic confusion could be overcome by molecular genetic assessments. ND gene analysis has contributed the clinical diagnosis of a simplex patient with either ND or PHPV.⁶ However, two sporadic patients with bilateral PHPV were negative for mutations in the ND gene.⁷ In our series of sporadic patients with bilateral PHPV, we could not find any abnormalities in the ND gene. Thus, the frequency of ND gene mutation is very low in PHPV populations. The molecular genetic assessment of the ND gene enables us to make early diagnosis and give useful information for the genetic counselling.

Acknowledgements

This work was supported by grants in aid for scientific research (14571681) from the Japanese Ministry of Education, Science and Culture.

Y Hatsukawa, T Nakao, T Yamagishi,
N Okamoto, Y Isashiki

Osaka Medical Centre and Research Institute for
Maternal and Child Health, Osaka, Japan

Correspondence to: Yoshikazu Hatsukawa, 840
Murodo-cho Izumi, Osaka, Japan 594-1101;
hatsu@mch.pref.osaka.jp

Accepted for publication 24 June 2002

References

- 1 Warburg M. Norrie's disease: a new hereditary bilateral pseudotumour of the retina. *Acta Ophthalmol (Copenh)* 1961;39:757-72.
- 2 Online Mendelian Inheritance in Man (OMIM). <http://www.ncbi.nlm.nih.gov/Omim/>
- 3 The Human Gene Mutation Database Cardiff. <http://www.uwcm.ac.uk/uwcm/mg/hgmd0.html>
- 4 Chen ZY, Battinelli EM, Fielder A, et al. A mutation in the Norrie disease gene (NDP) associated with X-linked familial exudative vitreoretinopathy. *Nat Genet* 1993;5:180-3.
- 5 Shastri BS, Pendergast SD, Hartzler MK, et al. Identification of missense mutations in the Norrie disease gene associated with advanced retinopathy of prematurity. *Arch Ophthalmol* 1997;115:651-5.
- 6 Chynn EW, Walton DS, Hahn LB, et al. Norrie disease: diagnosis of a simplex case by DNA analysis. *Arch Ophthalmol* 1996;114:1136-8.
- 7 Pendergast SD, Trese MT, Liu X, et al. Study of the Norrie disease gene in 2 patients with bilateral persistent hyperplastic primary vitreous. *Arch Ophthalmol* 1998;116:381-2.
- 8 Meindl A, Berger W, Meitinger T, et al. Norrie disease is caused by mutations in an extracellular protein resembling C-terminal globular domain of mucins. *Nat Genet* 1992;2:139-43.
- 9 Isashiki Y, Ohba N, Yanagita T, et al. Mutations in the Norrie disease gene: a new mutation in a Japanese family. *Br J Ophthalmol* 1995;79:703-8.
- 10 Edward DP, Mafee MF, Garcia-Valenzuela FE, et al. Coats' disease and persistent hyperplastic primary vitreous: role of MR imaging and CT. *Radiol Clin North Am* 1998;36:1119-31.

Primary monophasic synovial sarcoma of the conjunctiva

Synovial sarcoma is a malignant mesenchymal tumour, which makes up to 10% of all soft tissue sarcomas. It most often affects young adults and is commonly found in periarticular sites of the extremities. It may occur at other locations, including head and neck, heart, abdominal wall, mediastinum, and lung. Synovial sarcomas of the head and neck are rare, making up only 10% of all synovial sarcomas, and typically localising to the hypopharynx or parapharyngeal space. We report a first case of primary monophasic synovial sarcoma of the conjunctiva in a 29 year old man with no significant medical history, who developed an enlarging conjunctival lesion at the medial canthus of the right eye.

Case report

A 29 year old man presented with a 4 month history of a growing mass in the conjunctiva at the medial canthus of the right eye. Gross appearance was of a pink, fleshy, soft tumour, 10 mm in diameter, with a prominent feeding blood vessel (Fig 1). There was no significant past history, in particular, no apparent risk factors for acquired immunodeficiency or history of previous orbital irradiation. Ophthalmic examination showed no visual deficit. Computed tomograph (CT) scan showed no deep extension of the mass. General examination and CT staging of potential primary and metastatic tumour sites showed this to be a solitary lesion.

At surgery the tumour was found to be adherent to the medial rectus muscle and was excised with close margins. Excision was macroscopically complete, and the appearance was of a 1 cm diameter soft tissue lesion, vascular and without necrosis. Histology showed a spindle cell tumour with collagen bundles and frequent vessels in the stroma (Fig 2). Immunohistochemistry showed widespread EMA staining and scattered keratin positive cells. Stain for CD-99 and bcl-2 was positive. These are characteristic features of a monophasic synovial sarcoma. Stain for S-100 was also positive, which is a feature observed in one third of these tumours. Blocks were referred to an international sarcoma pathology reference centre.

Comment

There has been a significant recent rise in the reporting of ocular and ocular adnexal sarcomas. Almost all cases are associated with acquired immunodeficiency syndrome (AIDS), and irradiation of the orbits of children with hereditary retinoblastoma.

Figure 1 Gross tumour appearance of the conjunctival lesion seen in a 29 year old man at the medial canthus of the right eye.

Figure 2 Photomicrograph of tumour, showing a population of pleomorphic spindle-shaped cells with intervening rather hyaline-looking fibrous septae (scale: width of picture about 370 µm).

Adult Kaposi's sarcoma and childhood leiomyosarcoma are increased more than 10 000 fold with AIDS.¹ Hereditary retinoblastoma shows increased risk of sarcomas in the path of radiotherapy beam, especially if the patient is irradiated below 1 year of age.²

Synovial sarcoma is not of synovial origin, but is thought to be derived from as yet unknown multipotent stem cells capable of differentiating into mesenchymal and/or epithelial structures. It may be biphasic (consisting of epithelioid cells admixed with spindle cells) or monophasic (spindle cells with little or no evidence of epithelioid differentiation). Synovial sarcoma is associated with the chromosome translocation t(x;18)[p11.2;q11.2] causing a transcribed fusion product of two genes, *SYT* and *SSX1*, or *SSX2*. Diagnosis may be confirmed by fluorescence in situ hybridisation (FISH) or polymerase chain reaction (RT-PCR).³

Although primary orbital synovial sarcoma,⁴ and primary biphasic synovial sarcoma of the orbit⁵ have been reported, we can identify no cases of a primary monophasic synovial sarcoma presenting as a conjunctival tumour. Other soft tissue sarcomas may present as a primary tumour of the conjunctiva, including malignant fibrous histiocytoma of the conjunctiva,⁶ and primary conjunctival rhabdomyosarcoma.⁷ Benign leiomyoma of the caruncle⁸ and leiomyosarcoma of the conjunctiva have been reported,⁹ as has conjunctival liposarcoma.¹⁰

Complete surgical excision is the only curative option for adult soft tissue sarcomas. Adjuvant postoperative radiotherapy may reduce the risk of local relapse. Paediatric soft tissue sarcomas may respond to cytotoxic chemotherapy, but this is unusual in adult lesions. For soft tissue sarcoma of the conjunctiva, surgical adjuvant treatment with superficial radiotherapy (strontium-90) has been reported.⁷

Although rare, primary synovial sarcoma should be considered in the differential diagnosis of conjunctival masses.

Acknowledgements

We thank Professor C D M Fletcher, director of surgical pathology, Brigham and Women's Hospital, Boston, MA, USA for his advice.

M Votruba, J Hungerford

Moorfields Eye Hospital, City Road, London
EC1V 2PD, UK

M Votruba

Department of Molecular Genetics, Institute of
Ophthalmology, Bath Street, London EC1V 9EL, UK

P G S Cornes

Institute of Cancer Research, Cotswold Road,
Sutton, Surrey, SM2 5NG, UK

D Mabey

Ophthalmology Department, Guy's and St Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK

P Luthert

Department of Pathology, Institute of Ophthalmology, Bath Street, London EC1V 9EL, UK

Correspondence to: Dr Marcela Votruba, Department of Molecular Genetics, Institute of Ophthalmology, Bath Street, London EC1V 9EL, UK; m_votruba@altavista.co.uk

Accepted for publication 28 June 2002

References

- 1 **Goedert JJ.** The epidemiology of acquired immunodeficiency syndrome malignancies. *Semin Oncol* 2000;**27**:390-401.
- 2 **Abramson DH, Frank CM.** Second nonocular tumours in survivors of bilateral retinoblastoma. *Ophthalmology* 1998;**105**:573-80.
- 3 **Bridge JA.** Cytogenetics and experimental models of sarcomas. *Curr Opin Oncol* 1995;**7**:333-9.
- 4 **Ni C, Ma X.** Histopathologic classification of 1921 orbital tumors. *Yan Ke Xue Bao* 1995;**11**:101-4.
- 5 **Ratnatunga N, Goodlad J R, Sankarakumaran N, et al.** Primary biphasic synovial sarcoma of the orbit. *J Clin Pathol* 1992;**45**:265-7.
- 6 **Allaire GS, Corriveau C, Teboul N.** Malignant fibrous histiocytoma of the conjunctiva. *Arch Ophthalmol* 1999;**117**:685-7.
- 7 **Sekundo W, Roggenkamper P, Fischer HP, et al.** Primary conjunctival rhabdomyosarcoma: 2.5 years' follow-up after combined chemotherapy and brachytherapy. *Graefes Arch Clin Exp Ophthalmol* 1998;**236**:873-5.
- 8 **Heegaard S, Prause JU.** Leiomyoma of the caruncle. *Acta Ophthalmol Scand* 1998;**76**:731-3.
- 9 **White VA, Damji KF, Richards JS, et al.** Leiomyosarcoma of the conjunctiva. *Ophthalmology* 1991;**98**:1560-4.
- 10 **Miyashita K, Abe Y, Osamura Y.** Case of conjunctival liposarcoma. *Jpn J Ophthalmol* 1991;**35**:207-10.

Changing visual standards in driving: but a high proportion of eye patients still drive illegally

Many people drive either deliberately or unwittingly with inadequate vision to legally hold a licence.

A survey in Australia showed that 8% of drivers failed the state visual acuity requirements.¹ It is the duty of doctors to let their patients know if they do not fulfil the legal requirements.

In England group I drivers should be able to read a standard number plate at 20.5 metres in a good light using both eyes with correction worn if necessary. They should also have a binocular field of 120 degrees along the horizontal with no significant defect within 20 degrees of fixation in any direction. This should be tested with an Esterman binocular field test. Recent guidelines from the Driver and Vehicle Licensing Agency (DVLA) have changed with regard to visual field interpretation, allowing small areas of field loss within these areas to qualify for a pass for group I licence holders. In particular, patients with static long term field defects, particularly those who have a safe driving history who would previously have failed to meet the field requirements, may still be considered for a licence.²

This prospective clinic based audit is the first to use the licence plate test at 20.5 metres rather than a Snellen chart to quantify the size of the problem in a typical ophthalmology clinic in a district general hospital. The use of a number plate is important since Snellen acuity is known to be a poor predictor of an individual's ability to meet the required visual standard for driving³; this is probably because of the differing symbol format, lighting levels, and other conditions involved.

Participants and methods

In all, 156 consecutive patients were reviewed prospectively in general ophthalmology clinics with subspecialty interests in glaucoma and diabetes. All patients were asked if they held a group I (private car) or group II (large goods vehicles or passenger carrying vehicle) licence. Patients were tested in good light with a standard number plate (letters 79.4 mm high) at 20.5 metres using both eyes with their glasses when appropriate. They were given two attempts to read the number plate. Patients who were felt to be at risk of failing the field regulations (typically on the basis of monocular field tests for glaucoma or patients who had had bilateral panretinal photocoagulation) were asked to have an Esterman binocular field test. The notes of all patients who failed to achieve the visual standard for driving were reviewed and the patients were asked if they had ever been told not to drive before.

Results

A total of 156 patients were asked if they held a driving licence. Of these, 66 (average age 63.6, range 30-83, 52/66 male) held a group I driving licence, only two patients held a group II licence. Eleven patients (average age 72, range 62-81) who held a licence failed to meet the driving standard (Table 1).

One of the group II patients failed the test on acuity but was due to surrender his licence

in the next few months as he was retiring and had already ceased driving.

None of these patients had been told not to drive previously although the notes indicated vision (less than or equal to 6/18 in each eye) or field loss at the previous visit which should have made it clear that it was unlikely that these patients would be legally fit to drive in four of the cases. There was no documentation on whether these patients drove or had been advised not to in any of their notes. Three of the 11 patients had already ceased driving because they no longer felt confident enough but had retained their licences.

Nine of 11 patients failed to meet the driving standard because of poor visual acuity with two patients failing because of glaucomatous field loss. The new fields requirements would not have allowed either of these two patients to pass.

Conclusion

A total of 42% of patients seen in a busy eye clinic still held a driving licence and of these 17% did not fulfil the legal criteria to drive (7% of all patients seen). None of them had been informed previously that they should give up their licences despite evidence that at least 4/11 would have been unfit to drive from measurements made at a previous visit. Men were much more likely than women to be driving with inadequate vision (91% of those failing the driving standard in this study) and most of them were over the age of 70 (90%).

All patients should be asked if they drive or not and this should be recorded in the notes. If vision is inadequate for driving the notes should contain a statement that the patient has been informed of this and a letter sent to the general practitioner. This is particularly important from a medicolegal point of view since in one study half of the patients informed that they should surrender their licences continued to drive.⁴ Doctors should remain aware that they have a responsibility to alert patients that they should stop driving and that the patient should inform the DVLA. If the doctor does not do this then they may be liable to litigation should an accident occur.⁵ It may be worth pointing out to those patients who do not inform the DVLA of their poor eyesight that driving with inadequate vision may jeopardise insurance cover, as this may persuade many of them to stop driving.⁶

As previously reported the Snellen acuities did not correspond well with the ability to read a number plate.³ Ideally all eye clinics should have a number plate which can be viewed in good light from 20.5 metres for use when advice about driving is given. Unfortunately some number plates are easier to read than others and a "good light" is not defined in law so the test is not standardised. Although it is easy for a policeman to perform the test at the side of the road it is not a very reliable means of visual assessment particularly in equivocal cases and better standards would be helpful.

Most people in this study failed the test due to poor acuity rather than an inadequate field. It is possible that a few more people would have failed field tests if every driver had an Esterman binocular field test done. It is unlikely that the new more lenient field requirements will have a significant impact on the number of people seen in each clinic who drive illegally.

Whether these patients actually pose a significant risk to themselves or other road users is debatable; drivers with poor acuity appear to drive more carefully to compensate. However drivers with binocular field defects have

Table 1

Sex	Age	Best corrected visual acuity		
		RE	LE	
M	70	6/9+4	6/9+4	Failed on field
M	72	6/9	6/9+2	Failed on field
M	77	6/12-1	6/12-2	
M	67	6/12	6/12	
M	72	6/36	6/9+4	
M	81	6/18	6/18	
M	62	6/9-2	6/9-3	Group II licence holder
M	72	6/6-2	6/9	
M	74	6/9	6/36	
M	72	6/18	6/18	
F	74	6/18+3	6/9	

been estimated to have twice the normal rate of driving accidents in some studies.⁷⁻¹⁰ What is worrying is that patients who attend an eye clinic seem unlikely to have been spontaneously warned to stop driving and doctors should be more aware of their role in protecting both their patients and society from road traffic accidents.

**B J L Burton
J Joseph**

Ophthalmology Department, Central Middlesex
Hospital, Acton Lane, Park Royal, London
NW10 7NS, UK

Correspondence to: Ben Burton;
bjlburton@yahoo.co.uk

Accepted for publication 20 June 2002

References

- 1 McConnell RA, Spall AD, Hirst LW, *et al.* A survey of the visual acuity of Brisbane drivers. *Med J Aust* 1991;**155**:107-11.
- 2 Durston JC. DVLA requirements for visual fields testing. letter sent to all ophthalmologists registered to perform fields tests for the DVLA. (Letter) Drivers Medical Group. Swansea: Driver and Vehicle Licensing Agency, 19 Dec 2001.
- 3 Currie Z, Bhan A, Pepper I. Reliability of Snellen charts for testing visual acuity for driving: prospective study and postal questionnaire. *BMJ* 2000;**321**:990-2.
- 4 Mars JS. Drivers who defy the law. *BMJ* 1993;**307**:844-5.
- 5 Hawkins M. Commentary: Patients and doctors risk prosecution if they do not uphold the law. *BMJ* 1994;**309**:1058.
- 6 Paetkau ME, Taerum T, Hiebert T. Prevalence of illegal motor vehicle driving among visually impaired elderly patients in Alberta. *Can J Ophthalmol* 1988;**23**:301-4.
- 7 Keltner JL, Johnson CA. Visual function, driving safety and the elderly. *Ophthalmology* 1987;**94**:1180-8.
- 8 Fonda G. Legal blindness can be compatible with safe driving. *Ophthalmology* 1989;**96**:1457-9.
- 9 Keltner JL, Johnson CA. Visual function and driving safety. *Arch Ophthalmol* 1992;**110**:1967-8.
- 10 Johnson CA, Keltner JL. Incidence of visual field loss in 20,000 eyes and its relationship to driving performance. *Arch Ophthalmol* 1983;**101**:371-5.

Idiopathic parafoveal telangiectasis associated with a foveal pseudovitelliform lesion

Idiopathic parafoveal telangiectasis (IPT) and basal laminar drusen with pseudovitelliform lesions are both uncommon ocular findings.^{1,2} Gass classified parafoveal telangiectasis into several groups. Group 2 is characterised by bilateral acquired parafoveal telangiectasis that usually becomes clinically apparent later in life, in the fifth and sixth decade. The zones of telangiectasis tend to be symmetric and measure up to one disc diameter, with preferential involvement of the temporal parafoveal region. Typical findings are minimal retinal oedema, "right angle" veins, which drain the telangiectatic areas, underlying retinal pigment epithelial (RPE) alterations and superficial retinal refractile deposits. Gass has also described the development of a small, foveal yellow pseudovitelliform lesion in some patients, but no associated basal laminar drusen were noted.¹ Abnormal blood glucose metabolism may play a part in the development of IPT.³

Basal laminar or cuticular drusen are focal thickenings of the basement membrane of the RPE. Although they are sometimes difficult to

detect on clinical examination, these basal laminar drusen present a striking fluorescein angiographic picture of innumerable uniform, small, slightly raised, hyperfluorescent nodules.² Patients with basal laminar drusen may develop a yellowish exudative macular detachment ("pseudovitelliform lesion") that may resemble the foveal lesion characteristic of Best's vitelliform dystrophy. In some cases, the yellow material may gravitate to the inferior part of the detachment, producing a "pseudohypopyon" appearance. Typically, the pseudovitelliform material shows progressive staining with fluorescein dye during the course of the angiogram.²

This case report describes the presence of these two relatively uncommon conditions in the same eye of one patient. To the best of our knowledge, there is no previously reported case of simultaneous presentation of basal laminar drusen with pseudovitelliform lesion and parafoveal telangiectasis in one eye.

Case report

A 48 year old white woman presented for refraction with no other complaints. Around the age of 10, she presented with ptosis and a dilated pupil on the right eye and was diagnosed with a third nerve palsy. A examination ultimately revealed a craniopharyngioma for which she underwent resection. She did not receive any postoperative radiation treatment. Since the surgery, she has continued to have persistent ocular motility problems in the right eye. She also felt that her

vision has been poor, though stable, since the time of the surgery in the right eye. No other ocular findings were reported at that time.

After the surgery, she developed secondary panhypopituitarism for which she received hormone replacement therapy. A recent fasting blood sugar was normal, and diabetes was ruled out by her primary care physician. Her current medications include hormone replacement therapy (for the panhypopituitarism), consisting of prednisone 5 mg/day, levothyroxine sodium, desmopressin acetate, conjugated oestrogens, and medroxyprogesterone. Her family history was notable for cataract and diabetes mellitus. She has a 14 pack year smoking history, but quit 18 years ago.

On examination, best corrected visual acuity measured 20/40 in the right eye and 20/20 in the left eye. Visual fields were full to confrontation in both eyes. She had a non-reactive pupil on the right, but, by reverse testing, she did not have an afferent pupillary defect. She had marked limitation of movements of the right eye, particularly depression, elevation, and adduction. Abduction was also mildly reduced. Extraocular movements of the left eye were full. She had approximately 30 prism dioptres of exotropia of the right eye in primary position. Colour vision was 14 out of 14 in each eye, although somewhat slower on the right side.

External eye examination was within normal limits. Slit lamp examination disclosed trace nuclear opacities bilaterally. Contact lens biomicroscopy showed a cup:disc ratio of 0.3

Figure 1 (A) Fundus photograph of the right eye. The pseudovitelliform lesion is seen in the centre of the fovea (long arrow). Crystalline changes (short arrows) and temporal parafoveal telangiectasis (arrowhead) are also present. (B) Fundus photograph of the left eye. Multiple basal laminar drusen are seen. No pseudovitelliform lesion, telangiectatic vessels, or crystalline deposits can be observed.

Figure 2 (A) Early frame of a fluorescein angiogram. Subtle telangiectatic vessels are seen temporal to the foveal avascular zone in the right eye. Early fluorescence from multiple basal laminar drusen is observed deep to the retina. An area of blocked fluorescence is noted in the foveal centre corresponding to the pseudovitelliform lesion noted clinically. (B) Late frame of the same angiogram shows diffuse intraretinal leakage around the foveal avascular zone and staining of clusters of drusen.

in each eye. Both eyes showed evidence of numerous basal laminar hard drusen (best seen with indirect illumination), which formed typical clusters in numerous areas. There was no evidence of a pseudovitelliform lesion on the left. On the right side, there was a central yellowish lesion deep to the retina, which was consistent with a pseudovitelliform lesion. In addition, she appeared to have fine telangiectatic capillaries in the parafoveal retina most prominent temporally. The parafoveal retina was mildly thickened, and had a slight greyish sheen. Crystalline changes were also observed in the superficial retina (Fig 1).

A fluorescein angiogram was obtained transiting the right eye. The transit revealed telangiectasia of the parafoveal capillaries (most prominent temporally) with intraretinal leakage from these capillaries in later frames (Fig 2). The dye did not accumulate in cystoid spaces. There was no disc hyperfluorescence. Blocked fluorescence was observed under the fovea, corresponding to the pseudovitelliform lesion noted clinically. There was also punctate hyperfluorescence associated with the numerous basal laminar drusen present in both eyes (Figs 2A and 3). No evidence of telangiectasia or at least no evidence of leakage from telangiectatic capillaries was evident in the left eye (Fig 3).

Comment

This 48 year old woman with evidence of basal laminar drusen in both eyes and a vitelliform lesion in the right eye also has parafoveal telangiectasis in the same right eye.

She does not have any history of radiation treatment and she does not have diabetes. In addition, the distribution of telangiectatic capillaries and retinal leakage does not conform to the distribution of a branch retinal vein occlusion. Thus, the most likely explanation for the central vascular changes in the right eye is idiopathic parafoveal telangiectasis.³ Most of the patients with acquired IPT (group 2A according to Gass classification) present with bilateral disease.¹ However, some patients present with unilateral disease and some may present with asymmetric lesions and develop IPT in the other eye later in life.^{1,3} Our patient had typical findings including RPE changes, mild thickening of the retina, greyish sheen, characteristic crystalline deposits, and a typical fluorescein angiogram.³

Gass also noted that IPT could sometimes be associated with a yellow central spot.¹ He described five patients in group 2A that had such a spot, 100–300 µm in diameter in the

centre of the foveolar region.¹ The pseudovitelliform lesion in our patient, however, did not resemble the lesions described by Gass. Gass identified a yellow precipitate within the retinal layers. Our patient's lesion was deep to the retina and had the typical appearance of lesions associated with basal laminar drusen.² In addition, our patient, unlike those described by Gass, had clusters of basal laminar drusen, seen both clinically and angiographically. Financial interest: none.

E Margalit, R S Apte

Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA

S R Sadda

Doheny Retina Institute, University of Southern California Keck School of Medicine, Los Angeles, CA, USA

Correspondence to: Srinivas R Sadda, MD, The Doheny Retina Institute, University of Southern California Keck School of Medicine, 1450 San Pablo Street, Suite 3610, Los Angeles, CA 90033, USA; ssadda@dei.hsc.usc.edu

Accepted for publication 2 July 2002

References

- 1 Gass JD, Blodi BA. Idiopathic juxtafoveal retinal telangiectasis. Update of classification and follow-up study. *Ophthalmology* 1993;**100**:1536–46.
- 2 Gass JD, Jallow S, Davis B. Adult vitelliform macular detachment occurring in patients with basal laminar drusen. *Am J Ophthalmol* 1985;**99**:445–59.
- 3 Millay RH, Klein ML, Handelman IL, Watzke RC. Abnormal glucose metabolism and parafoveal telangiectasia. *Am J Ophthalmol* 1986;**102**:363–70.

Bilateral serous macular detachment in a patient with anaemic retinopathy secondary to gall bladder cancer

Various ocular complications of anaemia including hard exudates, cottonwool patches, frame-shaped haemorrhages, and Roth spots,

have been documented as anaemic retinopathy for many years. In addition, it has been reported that retinal venous tortuosity is directly related to severity of anaemia.¹ However, bilateral serous macular detachment has never been reported to be complicated with anaemic retinopathy. Bilateral serous detachment of the macula has been reported in some patients with systemic or ocular disorders, including lymphoma,² leukaemia, Vogt-Koyanagi-Harada syndrome, age related macular degeneration, and idiopathic central chorioretinopathy (ICSC).^{3,4} ICSC demonstrates central serous sensory detachments associated with leaks at the level of the retinal pigment epithelium. The classic features of ICSC are well known; this condition most commonly affects young or middle aged men between 30 and 50 years of age, occurs unilaterally and frequently in patients who have had a preceding stressful event, and has good visual prognosis.⁵ We describe an anaemic cancer patient with bilateral serous macular detachment similar to ICSC. We are unaware of other published reports similar to this case.

Case report

A 69 year old man admitted to the Kesennuma county hospital presented with mildly decreased vision and micropsia in the left eye for 1 week. Ocular history was unremarkable. Medical history was notable for gall bladder cancer diagnosed 2 months before presentation, for which the patient underwent surgery 6 weeks before presentation, and for anaemia. His haemoglobin had fallen to 8.0 g/dl secondary to the cancer 5 months before presentation. On consultation, his haemoglobin was 11.0 g/dl. The histological examination of the tumour showed undifferentiated carcinoma of the gall bladder.

Upon ophthalmological examination, best corrected visual acuity was 0.4 in the left eye and 0.6 in the right. Intraocular pressure was right eye 12 and left eye 14. Slit lamp examinations revealed no evidence of anterior chamber or vitreous inflammation in either eye. Both

Figure 3 Late frame of a fluorescein angiogram of the left eye shows punctate hyperfluorescence associated with numerous basal laminar drusen. There is no evidence of telangiectasia or retinal vascular leakage.

Figure 1 (Top) Colour photographs of (top left) right and (top right) left eyes show serous macular retinal detachment and multiple intraretinal haemorrhages including several Roth spots and mild venous dilation. (Bottom) Fluorescein angiography photographs of (bottom left) right and (bottom right) left eyes show bilateral round subretinal pools at the macula.

Figure 2 (Top) Colour photographs of (top left) right and (top right) left eyes appear almost normal except for several vanishing intraretinal haemorrhages. (Bottom) Fluorescein angiographic photographs of (bottom left) right and (bottom right) left eyes show no macular leakage and no subretinal pools.

fundi showed serous macular retinal detachment and multiple intraretinal haemorrhages including several Roth spots and mild venous dilation (Fig 1, top). In both eyes, fluorescein angiography revealed macular leakage in the early phases and round subretinal pools in the late phases (Fig 1, bottom).

We observed the patient conservatively and, 1 week later, his visual acuity recovered by one line in both eyes. Furthermore, his visual function was recovering gradually without any particular therapy such as systemic steroid treatment. Two months after his first visit to our department, best corrected visual acuity was 1.0 in both eyes. Fundi were almost normal except for several vanishing intraretinal haemorrhages (Fig 2, top). Bilateral serous macular detachment disappeared completely and fluorescein angiography showed no macular leakage and no subretinal pools (Fig 2, bottom). However, his anaemia was still unimproved at the time.

Comment

Bilateral central serous detachment similar to ICSC was resolved and vision recovered spontaneously, but the patient's anaemia did not improve. Although the pathogenesis of the bilateral serous macular detachment is unclear and histological proof is lacking in our case, pigment epithelial cell dysfunction of the bilateral macula and disruption of the blood-retinal barrier may occur as a result of anaemia or an idiopathic phenomenon. A case of bilateral serous retinal detachment resembling central serous chorioretinopathy (CSC) was reported to follow cervical steroid injection for treatment of chronic upper back pain. No drugs given to the patient in our department or the surgery department are known to cause serous macular detachment.⁶

This case highlights two points: that anaemic retinopathy from cancer is rarely complicated with bilateral serous macular detachment, which causes the patient moderate visual loss; and that a good return of vision may be possible spontaneously even if anaemia does not improve.

Proprietary interests, none.

H Kunikata, T Udono, S Nishikawa

Department of Ophthalmology, Kesennuma County Hospital, Miyagi, Japan

M Tamai

Department of Ophthalmology, School of Medicine, Tohoku University, Sendai, Japan

Correspondence to: Hiroshi Kunikata, MD, Department of Ophthalmology, Kesennuma County Hospital, 184 Tanaka, Kesennuma, Miyagi 988-0052, Japan; drkunikata@hotmail.com

Accepted for publication 5 July 2002

References

- 1 Aisen ML, Bacon BR, Goodman AM, *et al*. Retinal abnormalities associated with anemia. *Arch Ophthalmol* 1983;**101**:1049–52.
- 2 Kumar H, Garg SP, Kumar A, *et al*. Serous macular detachment in lymphoproliferative disorders. *Can J Ophthalmol* 1991;**26**:280–2.
- 3 Torron C, Melcon B, Ferrer E, *et al*. Central serous chorioidopathy. Long-term study. *Arch Soc Esp Oftalmol* 2000;**75**:103–8. (In Spanish)
- 4 Bandello F, Incorvaia C, Parmeggiani F, *et al*. Idiopathic multiple serous detachments of the retinal pigment epithelium followed by bilateral central serous chorioretinopathy: a case report. *Ophthalmologica* 2000;**214**:362–7.
- 5 Spaide RF, Campeas L, Haas A, *et al*. Central serous chorioretinopathy in younger and older adults. *Ophthalmology* 1996;**103**:2070–80.
- 6 Kao LY. Bilateral serous retinal detachment resembling central serous chorioretinopathy following epidural steroid injection. *Retina* 1998;**18**:479–81.

Choroidal detachment induced by dorzolamide 20 years after cataract surgery

One case of choroidal detachment induced by topical dorzolamide after filtration surgery has been reported.¹ We would like to report a case of a patient with ocular hypertension (OH), treated with topical timolol and dorzolamide who developed a choroidal detachment 20 years after cataract surgery.

Case report

A 70 year old white woman with a 12 year history of OH was treated effectively (intraocular pressure was 15 mm Hg in both eyes) by topical timolol 0.5 % once daily. She also had a 20 year history of bilateral extracapsular cataract extraction with no postoperative complications and no history of choroidal effusion or choroidal detachment. In February 2002, she was examined for a routine follow up. Her corrected visual acuity and intraocular pressure (IOP) were 6/10 and 22 mm Hg in both eyes. She was switched from timolol 0.5% to twice daily topical combination of timolol 0.5% and chlorhydrate dorzolamide 2%. Five days later, she came to the emergency department with headaches and ocular pain. Her corrected visual acuity was 6/10 in the right eye and 3/10 in the left eye. Her IOP was 25 mm Hg in the right and 35 mm Hg in the left eye. She had a bilateral angle closure. Ocular examination showed a bilateral choroidal detachment that was confirmed by an ocular echography. The topical combination of timolol and chlorhydrate dorzolamide was discontinued and 0.5% topical timolol once daily associated with 1% topical rimexolone four times daily were started. Five days later she was examined for follow up. Her corrected visual acuity and intraocular pressure were 6/10 and 16 mm Hg, the choroidal detachment and the functional symptoms had resolved in both eyes.

Comment

Selecting an appropriate pharmacological intervention for a patient with OH can reduce IOP by decreasing aqueous humour production by the ciliary processes—for example, carbonic anhydrase (CA) inhibitors. Because of its efficacy, the β adrenergic blocker—for example, timolol, is the gold standard compared with the other treatment. Dorzolamide may be used topically in addition to a β adrenergic blocker if the IOP cannot be reduced. In addition, dorzolamide can be used to prevent OH in patients undergoing cataract surgery. The predominant isoenzyme of CA in ciliary processes is isoenzyme II for which dorzolamide has a great affinity. The inhibition of isoenzyme II reduces IOP by decreasing in the production of aqueous humour. The presumed mechanism is a slowing of bicarbonate ion formation, which reduces sodium and fluid transport, resulting in lower intraocular pressure.

Considered to have few systemic side effects, dorzolamide may be associated with keratitis,² corneal oedema,³ and periorbital dermatitis.⁴ A combination of dorzolamide and timolol has also been associated with conjunctival hyperaemia and eye itching, blepharitis, eye oedema, foreign body sensation, lens opacity, and vitreous detachment. Other cases of choroidal detachment after filtering surgery linked to oral⁵ and topical¹ CA inhibitors have been reported. However, to the best of our knowledge, this is the first case of choroidal detachment occurring 20 years after ocular surgery. The mechanism of choroidal detachment with dorzolamide is probably due to hypotony caused by the reduction of intraocular pressure by the combination of timolol and dorzolamide.^{1,5} This mechanism has been mentioned in cases of choroidal detachment caused by latanoprost, a prostaglandin analogue used topically to reduce IOP, reported by Marques after filtration surgery.⁶ Another case of choroidal detachment has been reported in a patient who underwent left extracapsular cataract extraction with topically latanoprost prescribed immediately postoperatively.⁷

Ocular surgery, even if there is a history, seems to increase the risk of choroidal detachment when used as a pharmacological aqueous humour suppressant therapy—for example, dorzolamide or the combination of timolol and dorzolamide.

S Davani

Pharmacovigilance Centre, Besançon, France

B Delbosc

Department of Ophthalmology

B Royer

Department of Pharmacology

J-P Kantelip

Pharmacovigilance Centre

Correspondence to: Siamak Davani, MD, Pharmacovigilance Centre, J Minjot University Hospital, 25030 Besançon, France; davani@ufo-chu.univ-fcomte.fr

Accepted for publication 29 July 2002

References

- 1 **Fineman MS**, Katz LJ, Wilson RP. Topical dorzolamide-induced hypotony and ciliochoroidal detachment in patients with previous filtration surgery. *Arch Ophthalmol* 1996;**114**:1031–2.
- 2 **Taguri AH**, Khan MA, Sanders R. Marginal keratitis: an uncommon form of topical dorzolamide allergy. *Am J Ophthalmol* 2000;**130**:120–2.
- 3 **Konowal A**, Morrison JC, Brown SV, et al. Irreversible corneal decompensation in patients treated with topical dorzolamide. *Am J Ophthalmol* 1999;**128**:774–6.
- 4 **Delaney YM**, Salmon JF, Mossa F, et al. Periorbital dermatitis as a side effect of topical dorzolamide. *Br J Ophthalmol* 2002;**86**:378–80.
- 5 **Berke SJ**, Bellows AR, Shingleton BJ, et al. Chronic and recurrent choroidal detachment after glaucoma filtering surgery. *Ophthalmology* 1987;**94**:154–62.
- 6 **Marques Pereira ML**, Katz LJ. Choroidal detachment after the use of topical latanoprost. *Am J Ophthalmol* 2001;**132**:928–9.
- 7 **Gupta R**, Vernon SA. Choroidal detachment following extracapsular cataract extraction in a patient treated with latanoprost. *Br J Ophthalmol* 2001;**85**:1268.

MAILBOX

If you have a burning desire to respond to a paper published in the *BJO*, why not make use of our “rapid response” option? Log on to our website (www.bjophthalmol.com), find the paper that interests you, and send your response via email by clicking on the “eLetters” option in the box at the top right hand corner.

Providing it isn't libellous or obscene, it will be posted within seven days. You can retrieve it by clicking on “read eLetters” on our homepage.

The editors will decide as before whether to also publish it in a future paper issue.

Astigmatism and the analysis of its surgical correction

Thank you for the opportunity to reply to the letter from Alpkins concerning our recent article in the *BJO*.^{1,2}

Noel Alpkins is a widely respected contributor to many international meetings, having written comprehensively on the use of astigmatism vector analysis. His software program ASSORT is widely used for the planning of refractive surgery and provides many derived indices (transformations) from the vector analysis of both refractive and topographic astigmatism. Although the derived indices are summary measures, we have argued that their usefulness for statistical analysis is limited. This is because the perception of astigmatism is a psychophysical phenomenon altered by the orientation of the axis of astigmatism (the power meridians of the cornea and crystalline lens). Unfortunately, the perceptual response means that the measurement of the axis of astigmatism (which is with an arbitrary 180° scale) is non-linear in outcome terms, as related to visual acuity outcome. Astigmatism obliquity is the least desirable outcome but this is separated into two on the scale “with the rule” astigmatism (WTR), which is generally the most desirable outcome. Oblique astigmatism also separates the two groups of “against the rule” astigmatism (ATR) from the WTR astigmatism. Developments of vector analysis so far have not resolved this issue of non-linearity of the axis of astigmatism compared with the visual outcome. Alpkins recognised the relative value of WTR astigmatism and described how to plan refractive corrections using this principle (his Fig 10a) (reference 33 in our article).³ We suggested the WTR transformation would help eliminate the problem of divided oblique and WTR astigmatism, but this makes the use of vector analysis difficult and does result in data compression.

We agree that our understanding of astigmatism is incomplete. With over 4000 responses to a search for astigmatism on PubMed, there is much to know and yet more still unknown. The references cited in the article were simply representative or illustrative of the arguments discussed in the article. By way of apology, the correct reference for the “surgical error” (originally given as reference 34) in Figure 7, equation 20, and the relevant text page 1131 should in fact be reference 70, Alpkins's first article on vector analysis.⁴ The surgical error is the arithmetic result of the preoperative vector combined with the surgically induced vector (SIA), less the target induced vector (TIA), which is analogous to neutralising a lens with another of the opposite sign (hence the reverse direction arrow). This produces two outcome measures, the difference in magnitude and axis. However, as our article's discussion on obliquely crossed cylinders described, misalignment due to rotation of the corrective cylinder produces not only an error in cylinder magnitude and axis, but also a spherical power error. Because of this interdependence all three should be analysed together, but this produces statistical difficulties. One way around this problem is to use an appropriate summary measure of the outcome instead.

The surgical error may be applied to treatments targeting non-zero goals despite not addressing changes in corneal shape. As an outcome measure of the surgical process it is equally applicable to the arithmetic result of the SIA with the TIA as it is with the SIA and the preoperative astigmatism vector. The transformation of the error between the SIA and the preoperative astigmatism vector into the “difference vector” (which is a mathematically precise and absolute measure of the surgical error) unfortunately does not address the problem of non-linearity (that is, the relative value in terms of visual acuity

outcome) so is not useful as a summary measure of the outcome. However the difference may be useful in understanding the effects of the surgery (that is, as a process measure) and for deriving the “index of success.”

Alpkins describes the SIA “torque” effect with reference to the preoperative axis of astigmatism (or the TIA) not cited in our article.⁵ Torque needs to be distinguished from the effect of rotation of the corrective cylinder that is derived from the postoperative astigmatism value. Unfortunately, our discussion on the optical decomposition did not clearly state that the 45° polar value is derived from the postoperative result, thus correctly describing the rotation effect (as discussed with the obliquely crossed cylinder effects). We apologise for creating some confusion with the “torque” effect.

We agree that the healing response is connected to the surgical process; however, healing is a very individual response. Vector analysis in terms of the SIA can only reflect the surgical process. Although a “vector” could be used to represent the measurement of the healing response at any point in time, it may not be representative of the healing responses at other times because the healing process is continuous. Furthermore an individual's response may not be well represented by the aggregate or mean vectorial response, which as discussed, is compounded by the non-linearity problem of the separation of the oblique and ATR astigmatism axis values (see reference 104 in our article).⁶

In his early article² (reference 33) Alpkins discusses surgical treatment planning combining the topographic astigmatism values with the refractive values to produce an optimal corneal curvature. Alpkins suggests that the surgical emphasis is best directed towards a WTR result when there is a disparity between the values requiring some residual astigmatism after surgery. Without recognising Javal's rule, Alpkins, none the less, has ascribed a better relative value to ATR astigmatism suggesting that optimal treatment planning be based on this psychophysical phenomenon. As we stated “only using keratometric data for the planning of refractive surgery” would create a problem otherwise.

It is understandable that Alpkins feels that the concepts presented in our article are in conflict with some of his own, but these do not diminish the value of vector analysis as a process measure, particularly for individual cases. It is the use of vector analysis as an outcome measure relative to the visual acuity that was critically evaluated by our article.

N Morlet

Moorfields Eye Hospital, London, UK

D Minassian

International Centre for Eye Health, London, UK

J Dart

Moorfields Eye Hospital, London, UK

References

- 1 **Morlet N**, Minassian D, Dart J. Astigmatism and the analysis of its surgical correction. *Br J Ophthalmol* 2001;**85**:1127–38.
- 2 **Alpkins N**. A re-analysis of astigmatism correction. *Br J Ophthalmol* 2002;**86**:832.
- 3 **Alpkins NA**. New method of targeting vectors to treat astigmatism. *J Cataract Refract Surg* 1997;**23**:65–75.
- 4 **Alpkins NA**. A new method of analysing vectors for changes in astigmatism. *J Cataract Refract Surg* 1993;**19**:524–33.
- 5 **Alpkins NA**. Vector analysis of astigmatism changes by flattening, steepening, and torque. *J Cataract Refract Surg* 1997;**23**:1503–14.

6 Mathews JNS, Altman DG, Campbell MJ, *et al.* Analysis of serial measurements in medical research. *BMJ* 1990;**300**:230–5.

Autologous serum in epithelial defects: reply

Mukerji and colleagues have criticised several aspects of our study and justified their views with unrepresentative quotations from the literature.^{1,2}

Choice of time period before an epithelial defect can be described as “persistent”

There is no accepted definition of persistent epithelial defect (PED) that includes a time period. We favour the definition given in one text “when the epithelium fails to regrow over a defect within the expected time course.”³ For the purpose of a study the time course must be specified. Mukerji *et al* prefer 2 weeks⁴ whereas in another recent paper 10 days was chosen with the proviso that the study treatment could start earlier if there was progression to perforation.⁵ The penalty for patients at high risk of corneal melt, in the presence of a persistent defect, is substantial. In our study 2/13 patients had an epithelial defect for less than 2 weeks before inclusion in the study; Mukerji *et al* can ignore the data from these patients if they wish.

Washout period with preservative-free artificial tears

No “washout period” was used in this study, as we were trying to identify whether serum would have an additional effect on epithelial healing over preservative-free artificial tears and conventional therapy in patients with severe ocular surface disease. We were not trying to compare the efficacy of serum against preservative-free lubricants in healing PEDs. Conventional therapy was continued as serum alone could not fully address all the ocular surface problems, including aqueous tear deficiency and eyelid trauma, so that giving serum without continuing the other treatments may have caused harm to some of the patients. Other studies have adopted similar protocols with a PED defined as a defect that persisted “despite conventional treatment such as artificial tears or extended wear contact lenses” with no washout period⁴ or that allowed a reduction in the 10 day wash out period if corneal ulceration progressed.⁵ In a clinical study some ethics committees may not condone the treatment of persistent defects without non-preserved antibiotic prophylaxis against bacterial keratitis.

Keratoplasty patients being treated without waiting for the corneal epithelial defect to heal by itself

These patients had both failed previous grafts because of corneal perforation resulting from PEDs and one patient had recurrent epithelial breakdown, responding to the re-introduction of serum drops, after their initial withdrawal. We thought that, for some readers, this might be useful data to add to this descriptive study.

The rationale behind the use of 100% serum when previous studies have proved the efficacy of a 20% solution

The previous study Mukerji *et al* quote is, like ours and all the other studies on this subject, a descriptive study and no more proves that serum drops at 20% work than does our own with 50% and 100%. Other studies, all uncontrolled, have used from 20%–30% serum^{4–6} for

both persistent defect and dry eye. All these studies use empirical regimens for serum concentration and dosing frequency. Unlike Mukerji *et al*, we have some patients (one reported in the study) who prefer 100% serum to 50%. Mukerji *et al* are probably also unaware of our study demonstrating that 100% serum is less toxic than 50% serum to cultured corneal epithelial cells⁷; this provides some laboratory data to support the use of 100% serum. Lastly, the manufacture of 100% serum requires less handling so reducing the risk of contamination.

The use of the slit lamp micrometer

Mukerji *et al* have missed the point that the treatment end point was closure of the defect, for which their proposed technique is inappropriate, rather than rate of closure, for which it would be ideal.

The deficiencies in our study are not the points that Mukerji *et al* have made but the fact that it was uncontrolled. The study was planned as a randomised controlled trial but could not be carried out as such for the reasons alluded to in the last paragraph. These regulatory problems are being overcome in the United Kingdom. We should all hope to see randomised treatment trials carried out in this area as well as the laboratory studies necessary to support the clinical application of serum.

J Dart

Moorfields Eye Hospital, London, UK

A Poon

Royal Victorian Eye and Ear Hospital, Melbourne, Australia

Correspondence to: John Dart, MA, DM, FRCS, Moorfields Eye Hospital, 162 City Road, London EC1V 2PD, UK; j.dart@ucl.ac.uk

References

- 1 Mukerji N, Sinha R, Vajpayee RB. Role of autologous serum in persistent epithelial defects. *Br J Ophthalmol* 2002;**86**:832.
- 2 Poon AC, Geerling G, Dart JKG, *et al.* Role of autologous serum in persistent epithelial defects. *Br J Ophthalmol* 2001;**85**:1188–97.
- 3 Macaluso DC, Feldman ST. Persistent epithelial defects and sterile ulceration. Pathogenesis of sterile corneal erosions and ulcerations. In: Krachmer J, Mannis M, Holland E, eds. *Cornea; fundamentals of cornea and external disease*. Vol 1. Chapter 10; St Louis: Mosby, 204.
- 4 Tsubota K, Goto E, Simmer S, *et al.* Treatment of persistent epithelial defect by autologous serum application. *Ophthalmology* 1999;**106**:1984–9.
- 5 Bonini S, Lambiase A, Rama P, *et al.* Topical treatment with nerve growth factor for neurotrophic keratitis. *Ophthalmology* 2000;**107**:1347–51.
- 6 Fox RI, Chan R, Michelson J, *et al.* Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. *Arthritis Rheum* 1984;**29**:577–83.
- 7 Geerling G, Daniels JT, Dart JK, *et al.* Toxicity of natural tear substitutes in a fully defined culture model of human corneal epithelial cells. *Invest Ophthalmol Vis Sci* 2001;**42**:948–56.

Sclera substitutes: a cautionary note

In their article in the *BJO*,¹ Mehta and Franks provide a valuable and timely review of the use of human sclera in ophthalmic surgery. The article was prompted by the implications of using human sclera in the light of the as yet unquantified risk of iatrogenic transmission of variant Creutzfeldt-Jakob disease (vCJD).

The authors list a number of alternatives to sclera, including dura mater. While they point out that the surgical use of dura mater has itself resulted in a significant number of cases of transmission of classic CJD, it is also stated that a commercial preparation of dura mater, treated to reduce the risk of CJD transmission, is available. In the United Kingdom, the Medical Devices Agency (MDA) withdrew the licences issued under the Surgical Materials Act 1971 for the two available commercial preparations of dura mater in 1991 and 1992, respectively. According to the MDA, no products containing human dura mater are currently licensed for clinical use in the United Kingdom. It is clearly not appropriate to recommend use of an unlicensed product whatever claims have been made about its preparation. It should be noted that individuals who have received dura mater allografts are excluded from subsequently donating tissues for transplantation.² Finally, it would be important to know whether any ophthalmic surgeons in the United Kingdom have in fact used preparations of dura mater since 1992 as further guidance may need to be sought.

W J Armitage

Director of Tissue Banking, Division of Ophthalmology, University of Bristol, Bristol Eye Hospital, Lower Maudlin Street, Bristol BS1 2LX, UK; w.j.armitage@bristol.ac.uk

References

- 1 Mehta JS, Franks WA. The sclera, the prion, and the ophthalmologist. [Perspective] *Br J Ophthalmol* 2002;**86**:587–92.
- 2 Advisory Committee on the Microbiological Safety of Blood and Tissues for Transplantation (MSBT). *Guidance of the microbiological safety of human organs, tissues and cells used in transplantation*. London: Department of Health, August 2000 (www.doh.gov.uk/msbt/).

Preoperative management in cataract surgery for high myopes

We enjoyed reading the recent series of papers by Seward *et al* which illustrate some management issues for a high myope (approximately –12D) presenting with bilateral cataract.¹ Packard recommends preoperative fundal assessment and prophylactic treatment if necessary while Allen advocates a retinal opinion before discussing the risks of cataract surgery with the patient. The accompanying overview by Seward stresses the need for retinal opinion, and we are told that the patient received prophylactic laser treatment to a peripheral round break before cataract surgery.

It is not routine in our hospital to obtain a retinal opinion on high myopes before cataract surgery and the evidence for prophylactic treatment of asymptomatic retinal breaks and lattice degeneration is not good. With the assistance of the American Academy of Ophthalmology preferred practice pattern retinal panel, Wilkinson conducted an extensive literature search on this topic, reviewing all relevant papers in the English language over the preceding 35 years.² His conclusion was that, on the basis of good quality (level 1) data, only symptomatic retinal tears warranted routine prophylactic treatment. Lesser quality (level 2) evidence also indicated that treatment was not required for lattice degeneration in asymptomatic myopic eyes, and only rarely indicated for asymptomatic atrophic holes in phakic eyes. He also highlighted the best published (level 2) evidence for prophylactic treatment of fellow eyes

following retinal detachment, which indicates that the benefit of treating lattice degeneration is modest at best and of no value in eyes with more than 6 dioptres of myopia or with more than 6 clock hours of lattice degeneration.

As evidence based medicine quite rightly gains importance in our clinical decision making, it is pertinent to question some of the traditional treatment options which have been handed down to us. We feel that this otherwise excellent overview of the problems of cataract surgery in myopia has not satisfactorily discussed the question of prophylactic retinal treatment and has, perhaps unwittingly, advocated the continued use of an ineffective clinical practice.

C T Ung, J M Twomey, R H Gray

Eye Department, Taunton and Somerset NHS Trust,
Muggrove Park, Taunton TA1 5DA, UK

Correspondence to: C T Ung

References

- 1 Seward H, Packard R, Allen D. Management of cataract surgery in a high myope. *Br J Ophthalmol* 2001;**85**:1372–8.
- 2 Wilkinson CP. Evidence-based analysis of prophylactic treatment of asymptomatic retinal breaks and lattice degeneration. *Ophthalmology* 2000;**107**:12–16.

Amniotic membrane transplantation

We read with keen interest the article by Espana *et al* on the use of amniotic membrane transplantation (AMT) for ocular surface reconstruction after excision of large neoplasia.¹ We fully endorse their views that AMT is rapidly evolving as a viable option in the management of a wide spectrum of ocular surface disorders because of a multitude of beneficial properties that it possesses. However, we would like to clarify a few misgivings in some crucial areas of concern.

As the authors have aptly emphasised total eradication of tumour cells from the ocular surface is essential for successful treatment and minimising recurrences. To achieve this objective, in our own clinical experience and in the literature, frozen section controlled excision (FSCE) of the tumour, combined with a double freeze-thaw cycle of cryotherapy is now a recognised, accepted technique in a majority of centres across the world.^{2–4} It has been reported to achieve very effective tumour control and reduce recurrence rates from as high as 24–50% to a negligible 4.5%.³ It is especially useful in patients with conjunctival malignant melanoma where lack of pigmentation may not always be indicative of a tumour free margin. Although the authors have reported a relatively low recurrence rate of 10% in cases of conjunctival intraepithelial neoplasia (CIN) even without this technique, we strongly feel that FSCE should be routinely used when dealing with such lesions.

Secondly, it is our considered opinion that in case tumour excision is being carried out on the basis of clinical parameters alone, without confirmation with FSCE, a double freeze-thaw cycle of cryotherapy (in contrast to the single freeze thaw cycle used in this study) is advisable.^{3,4} Moreover, leaving a clinically assessed tumour free margin of 3–4 mm, as described, may not be safe enough and it may be more prudent to leave a healthy margin of at least 5 mm, even at the cost of sacrificing a bit of extra normal tissue, thereby gaining a lower probability of tumour recurrence and patient morbidity in the bargain.

Finally, we would like to say that the results achieved by the authors are commendable by any standards and indicate a really meticulous surgical technique and painstaking follow up.

M S Bajaj, A Panda, N Pushker, Balasubramanya R

RP Centre, All India Institute of Medical Sciences,
New Delhi, India

Correspondence to: Mandeep Bajaj;
msbajaj32@hotmail.com

References

- 1 Espana EM, Prabhasawat P, Grueterich M, *et al*. Amniotic membrane transplantation for reconstruction after excision of large ocular surface neoplasias. *Br J Ophthalmol* 2002;**86**:640–5.
- 2 Polchareon W, Pilch BZ, Jakobiec FA. Frozen section diagnosis in ophthalmic surgery. *Int Ophthalmol Clin* 1999;**39**:195–211.
- 3 Murat T, Char DH, Crawford B, *et al*. Intraepithelial and invasive squamous cell carcinoma of the conjunctiva: analysis of 60 cases. *Br J Ophthalmol* 1999;**83**:98–103.
- 4 Panda A, Sharma N, Sen S. Massive corneal and conjunctival squamous cell carcinoma. *Ophthalmic Surg Lasers* 2000;**31**:71–2.

Surgical endoscopic dacryocystorhinostomy

We have read the thought provoking article by Yung and Hardman-Lea on their experience with surgical endoscopic dacryocystorhinostomy (DCR).¹ We appreciate the success rates achieved by them, which are among the highest in endonasal lacrimal surgery and comparable with those of external DCR in most centres of the world. We would like to discuss some relevant issues and seek clarifications about certain controversial areas.

The authors have adequately described their surgical technique for negotiating nasolacrimal duct (NLD) as well as common canalicular obstructions.¹ However, they have not mentioned the technique they employed in tackling more proximal blocks—that is, those involving the upper, lower, or both canaliculi in their group of such patients (13 cases).

Undoubtedly, these obstructions are the most difficult to treat and various surgical² and laser assisted treatments⁴ have been described in the literature, with variable success rates.

A detailed elucidation of how the authors approached the individual lacrimal canaliculi from the endonasal route to relieve the obstruction will be extremely valuable to the readers as a whole, and to dacryologists in particular.

Silicone stents have become an almost universally accepted adjunct in lacrimal surgery for enhancing success rates in cases with relatively poor prognosis. However, we would like to express serious reservations about keeping the stent in situ permanently, as described by the authors in proximal canalicular obstructions. Most of the previous studies have recommended placement of the stent for a period ranging from 3–9 months.² Although silicone stents are absolutely inert and usually harmless, on prolonged placement they can act as a nidus for granuloma formation and infection, leading to failure of the lacrimal procedure in the long run.^{5,6} Moreover, inadvertent traction to the nasal end can result in slitting of the puncta and cheese wiring of the canalicular complex, whereas gradual ascent in the nasal cavity can lead to prolapse of the tube at the medial canthus.⁷ So, in our

opinion, the time period of stent placement should be optimised and permanent placement could have long term deleterious effects.

M S Bajaj, N Pushker, Balasubramanya R, A Rani
RP Centre, All India Institute of Medical Sciences,
New Delhi, India

Correspondence to: M S Bajaj;
msbajaj32@hotmail.com

References

- 1 Yung MW, Hardman-Lea S. Analysis of results of surgical endoscopic dacryocystorhinostomy: effect of the level of obstruction. *Br J Ophthalmol* 2002;**86**:792–4.
- 2 Wearne MJ, Beigi B, Davis G, *et al*. Retrograde intubation dacryocystorhinostomy for proximal and mid-canalicular obstruction. *Ophthalmology* 1999;**106**:2325–9.
- 3 Piaton JM, Keller P, Limon S, *et al*. Holmium:YAG and neodymium:YAG assisted transcanalicular dacryocystorhinostomy: results of 317 first procedures. *J Fr Ophthalmol* 2001;**24**:253–64.
- 4 Steinhauer J, Norda A, Emmerich KH, *et al*. Laser canaliculoplasty. *Ophthalmologie* 2000;**97**:692–5.
- 5 Allen K, Berlin AJ. Dacryocystorhinostomy failure: an association with nasolacrimal silicone intubation. *Ophthalmic Surg* 1989;**20**:486–9.
- 6 Önerci M, Orhan M, Ögretmenoglu O, *et al*. Long term results and reasons for failure of intranasal endoscopic dacryocystorhinostomy. *Acta Otorhinol* 2000;**120**:319–22.
- 7 Brookes JL, Olver JM. Endoscopic endonasal management of prolapsed silicone tubes after dacryocystorhinostomy. *Ophthalmology* 1999;**106**:2101–5.

Sclerectomy with collagen implant

Tan and Hitchings should be commended on attempting to tackle the issue of sclerectomy with collagen implant.¹ Nevertheless we do feel that their fundamental points and principal arguments merit reconsideration.

The authors state categorically that “long term outcomes do not exit for the newer non-penetrating surgery technique” when, in fact, long term (43.2 months (SD 14.3)) results for deep sclerectomy with collagen implant have been published some time ago.² The study provided a qualified success rate of 94.8% and the complete success rate of 61.9% after 60 months (survival analysis), with a mean IOP at end of follow up of 11.8 (SD 3) mm Hg. The study reported no surgically induced cataract in the whole series of 105 patients.

The authors, unfortunately, failed to cite a landmark study³ comparing deep sclerectomy without an implant with trabeculectomy in the two eyes of the same patient in a prospective randomised fashion. At 12 months, mean IOP reduction was 12.3 (4.2) mm Hg (sclerectomy) versus 14.1 (6.4) mm Hg (trabeculectomy) ($p = 0.15$), and an IOP ≤ 21 mm Hg was achieved in 36 (92.3%) and 37 eyes (94.9%) ($p = 0.9$), respectively. The authors of this study concluded that deep sclerectomy might provide comparable IOP reduction with fewer complications in the management of primary open angle glaucoma.

Furthermore, the authors cite a study by Gandolfi (personal communication) supposedly providing evidence that “trabeculectomy produces lower and better sustained IOP control than either viscocanalostomy or deep sclerectomy.” The authors fail to mention however, that in this particular study postoperative YAG goniopunctures were considered as a failure criterion. Excluding goniopuncture from the success criteria would easily be

compared to considering laser suture lysis or even YAG capsulotomies to be failure criteria of glaucoma or cataract surgeries. Furthermore, Gandolfi concluded that deep sclerectomy was associated with lower perturbation of lens nuclear transparency (personal communication, January 2002).

In another point worthy of reconsideration the authors cite a study⁴ that allegedly draws attention to high rates of hypotony and hyphaema after intraoperative conversion of deep sclerectomy to trabeculectomy following accidental intraoperative perforation of the trabeculo-Descemet's membrane (TDM). However, the authors again fail to mention, when quoting this specific study, that "when deep sclerectomy is complicated with a perforation of the TDM, the long term success rate of the surgery is similar to that of trabeculectomy." This conclusion would encourage the surgeons to start their surgery as a deep sclerectomy, knowing that in case of a perforation and a subsequent transformation to trabeculectomy, the chances of success would be similar to initial trabeculectomy.

The authors of the paper at hand compare in their figures, to each other, for viscocanalostomy, deep sclerectomy without an implant, deep sclerectomy with collagen implant, and deep sclerectomy without suturing the superficial flap, thus drawing certain conclusions. The different techniques have one thing in common, the element of non-perforation. It is not useful to compare apples and pears.

A major factor in the conflicting, often contradictory, results available is the element of long learning curves.

As an example one group reported 0% success rate in their first series of viscocanalostomy patients⁵ and then presented their second series with a success rate of 15%.⁶

The same group also analysed the depth of their dissection of the deep sclera⁷ to find that they dissected too superficially in 48% of their cases and too deeply in 17%; meaning that the proper depth of dissection, which should bisect transversally the Schlemm's canal deroofing it, was not achieved in the majority of their cases.

To achieve successful non-penetrating surgery, the dissection of the deep sclerectomy needs to be correct. This entails a total excision of corneal stroma behind Descemet's membrane and the excision of the inner wall of Schlemm's canal and the juxtacanalicular trabeculum. An implant has to be used to maintain the scleral space patent.⁸ Laser goniotomy should be performed at any postoperative stage when IOP mounts beyond the target pressure.

We do, however, wholeheartedly agree with the authors on the importance of conducting a large scale multinational randomised prospective trial as the only possible method to compare non-penetrating glaucoma surgery, or any other new surgical practice, to trabeculectomy.

T Shaarawy

Glaucoma Unit, Memorial Research Institute of Ophthalmology, Giza, Egypt

A Mermoud

Glaucoma Unit, University of Lausanne, Switzerland

Correspondence to: Dr Shaarawy; tshaarawy@yahoo.com

References

- 1 Tan JCH, Hitchings R. Non-penetrating glaucoma surgery: the state of play. *Br J Ophthalmol* 2001;**85**:234-7.
- 2 Shaarawy T, Karlen M, Schnyder C, et al. Five-year results of deep sclerectomy with

collagen implant. *J Cataract Refract Surg* 2001;**27**:1770-8.

- 3 El Sayyad F, Helal M, El Kholify H, et al. Nonpenetrating deep sclerectomy versus trabeculectomy in bilateral primary open-angle glaucoma. *Ophthalmology* 2000;**107**:1671-4.
- 4 Sanchez E, Schnyder CC, Mermoud A. [Comparative results of deep sclerectomy transformed to trabeculectomy and classical trabeculectomy.] *Klin Monatsbl Augenheilkd* 1997;**210**:261-4.
- 5 Jonescu-Cuypers C, Jacobi P, Konen W, et al. Primary viscocanalostomy versus trabeculectomy in white patients with open-angle glaucoma: a randomized clinical trial. *Ophthalmology* 2001;**108**:254-8.
- 6 Dietlein TS, Krieglstein GK. Morphology and pressure-reducing efficacy after viscocanalostomy. Closed meeting of the European Glaucoma Society. Paris: European Glaucoma Society, 2001.
- 7 Dietlein TS, Luke C, Jacobi PC, et al. Variability of dissection depth in deep sclerectomy: morphological analysis of the deep scleral flap. *Graefes Arch Clin Exp Ophthalmol* 2000;**238**:405-9.
- 8 Shaarawy T, Nguyen C, Schnyder C, et al. Comparative study between deep sclerectomy with and without collagen implant: long term follow-up. *Invest Ophthalmol* 2001;**42**:S544.

Corneal tattooing

We were pleased to read the article by Pitz and associates on a pragmatic approach to the management of corneal tattooing.¹ Though permanent colouring of unsightly corneal scars is considered an ancient form of treatment² it has therapeutic value for a distinct group of patients.^{1,3} The authors are to be congratulated on their achievement in corneal tattooing by using the indigenous material injections (commercially available ink, thus no problem to obtain) into the corneal stromal lamellae in a modified manner.¹ They have rightly pointed out that to date there is no optimal method of surgical technique for corneal tattooing. However, we feel it is always better to apply the colouring agents intralaminally for two reasons: (1) it provides uniform distribution of the colour when applied on a smooth lamellar surface as against the irregular epithelium which is expected in these eyes; (2) it minimises the chances of development of an irritable eye which is expected when it is applied on the corneal surface.

Besides its therapeutic and cosmetic use for iris defects³ most of the time corneal tattooing is indicated in unsighted eyes with corneal scar.¹⁻³ These eyes are bound to have an irregular surface. Thus, surface application of the dye, besides providing a patchy appearance, often is responsible for a surface irritant. Sometimes the lesion also requires an additional procedure of EDTA chelation as mentioned by the authors.¹ Considering these facts, intralaminar application of the colouring agent for corneal tattooing should be an accepted procedure.

A Panda, M S Pangtey, P Sony

D II, 36 Ansari Nagar, All India Institute of Medical Sciences, New Delhi, India 110029

Correspondence to: Dr Panda; anitap49@yahoo.com

References

- 1 Pitz S, John R, Frisch L, et al. Corneal tattooing: an alternative treatment for disfiguring corneal scars. *Br J Ophthalmol* 2002;**86**:397-9.
- 2 Gifford SR, Steinberg A. Gold and silver impregnation of cornea for cosmetic puposes. *Am J Ophthalmol* 1927;**10**:240-7.

- 3 Panda A, Mohan M, Chawdhary S. Corneal tattooing—experiences with "lamellar pocket procedure." *Ind J Ophthalmol* 1984;**32**:408-11.
- 4 Anastas CN, McGhee CNJ, Webber SK, et al. Corneal tattooing revisited: excimer laser in the treatment of unsightly leucomata. *Aust NZ J Ophthalmol* 1995;**23**:227-30.
- 5 Reed JW. Corneal tattooing to reduce glare in cases of traumatic iris loss. *Cornea* 1994;**13**:401-5.

Acanthamoeba and disinfecting contact lens solutions

I read with interest the article by Hiti *et al*¹ on the susceptibility of *Acanthamoeba* to a multi-purpose disinfecting contact lens solution and two hydrogen peroxide systems. The association between *Acanthamoeba* keratitis and contact lens wear is now firmly established. Thus, the use of contact lens disinfecting solutions effective at killing *Acanthamoeba* organisms is important in preventing corneal infections. I would like to make a few comments on this article.

The lack of standard methods for testing disinfecting solutions against *Acanthamoeba* represents a critical problem when sensitivity assays are set up.² The authors say that 1 ml of disinfectant per well was applied in 24 well plates, but the amount of *Acanthamoeba* suspension distributed in each well is missing. PHMB (0.0005%) was found to be ineffective against *A. hatchetti* and *A. lenticula* cysts after 8 hours' exposure. This is not surprising. Indeed, at concentrations (0.5–15 µg/ml) used in commercial contact lens solutions, PHMB is almost ineffective against amoeba cysts.³⁻⁶ PHMB concentrations ranging from 45–90 µg/ml are needed to kill 99.9% of *Acanthamoeba* cysts in under 1 hour of exposure.⁷

The authors observed that a one step 3% H₂O₂ system with catalase was ineffective against *Acanthamoeba* cysts after 8 hours' exposure. Silvary *et al*⁸ reported similar results. Because the catalyst is present from the very beginning of the disinfection step, the H₂O₂ is neutralised long before any disinfection can occur. Therefore, adequate exposure time before neutralisation is crucial.

The authors also found that a two step 0.6% H₂O₂ system was effective against *A. castellanii* and *A. hatchetti* cysts after 8 hours' exposure. However, Zanetti *et al*⁹ observed that an equivalent dilution of 3% H₂O₂ was ineffective against the cysts of a corneal isolate of *A. castellanii* after 9 hours' exposure. These variations in susceptibility may depend on inherent strain differences.² Therefore, unlike the authors, I would not recommend the two step 0.6% H₂O₂ system as a safe disinfectant against *Acanthamoeba*. From previous data,^{6,8,9} I suggest that the following measures should result in less contact lens case and contact lens contamination, thereby possibly reducing the risk of microbial keratitis.

- Naturally: wash hands before handling contact lenses

- Use "one day" disposable contact lenses

If other types are preferred:

- Use a two step 3% H₂O₂ system and neutralise after 9 hours' exposure (overnight)
- Replace the contact lens case regularly (preferably every 2 weeks).

A Pinna

Institute of Ophthalmology, University of Sassari, Viale San Pietro 43A, 07100 Sassari, Italy; apinna@uniss.it

References

- 1 Hiti K, Walochnik J, Haller-Schober EM, *et al*. Viability of Acanthamoeba after exposure to a multipurpose disinfecting contact lens solution and two hydrogen peroxide systems. *Br J Ophthalmol* 2002;**86**:144–6.
- 2 Meisler MD, Rutherford I. Acanthamoeba and disinfection of soft contact lenses. *Rev Infect Dis* 1991;**13**:S410–2.
- 3 Hugo ER, McLaughlin WR, Oh K, *et al*. Quantitative enumeration of Acanthamoeba for evaluation of cyst inactivation in contact lens care solutions. *Invest Ophthalmol Vis Sci* 1991;**32**:655–7.
- 4 Silvany RE, Dougherty JM, McCulley JP. Effect of currently available contact lens disinfection systems on Acanthamoeba castellanii and Acanthamoeba polyphaga. *Ophthalmology* 1990;**97**:286–90.
- 5 Silvany RE, Dougherty JM, McCulley JP. Effect of contact lens preservatives on Acanthamoeba. *Ophthalmology* 1991;**98**:854–7.
- 6 Zanetti S, Fiori PL, Pinna A, *et al*. Susceptibility of Acanthamoeba castellanii to contact lens disinfecting solutions. *Antimicrob Agents Chemother* 1995;**39**:1596–8.
- 7 Burger RM, Franco RJ, Drlaca K. Killing Acanthamoebae with polyaminopropyl biguanide: quantitation and kinetics. *Antimicrob Agents Chemother* 1994;**38**:886–8.
- 8 Grey TB, Cursons RTM, Sherwan JF, *et al*. Acanthamoeba, bacterial, and fungal contamination of contact lens storage cases. *Br J Ophthalmol* 1995;**79**:601–5.
- 9 Pinna A, Sechi LA, Zanetti S, *et al*. Bacillus cereus keratitis associated with contact lens wear. *Ophthalmology* 2001;**108**:1830–4.

Squamous cell carcinoma of the conjunctiva

The article by McKelvie *et al*¹ is especially noteworthy as it highlights a number of interesting observations.

In the first instance, the authors highlight that conjunctival squamous cell carcinoma (SCC) is not as uncommon worldwide as reported earlier.²

Recurrence of ocular surface squamous neoplasia (OSSN) is common, with significantly increased risk for older patients, large size, high proliferation index (Ki-67 score), and positive surgical margins (total recurrence being 27%). For control of local disease, exenteration may be the answer. The larger the diameter of the mass, the more accurate is the clinical diagnosis. A high proliferation index increases the predictability of recurrences and serial impression cytology is an extremely useful tool for early detection of recurrences.

Intraocular invasion, corneal and/or corneal scleral invasion, and death due to metastasis are the other important findings.

We have been working in this field since 1977 and managed a large number of eyes at two tertiary eye care centres of developing countries (All India Institute of Medical Sciences, India; 86 in 22 years, BP Koirala Institute of Health Sciences, Nepal; seven in 2 years). We would like to comment on a few aspects that have been reported by the authors.¹

We are in agreement with the authors that SCC is not uncommon, which is true even in our part of the world. From the histopathological analysis revealing involvement of the margins in a few cases, it is not clear whether the cases were managed by frozen section controlled excision (FSCE) or not (as one tends to remove all the histopathologically proved lesions if the frozen section facility is available during surgery).

The authors have very rightly documented the risk factors for recurrence. However, by employing FSCE we did not come across a recurrence in any of our patients and we feel that FSCE combined with double freeze-thaw cryotherapy to the surgical margins is a useful tool for tumour management and should become mandatory in all cases. We had a clinical impression of recurrence in three eyes which after removal revealed granulomatous lesions on histopathology. However, as we have operated on a large number of recurrent lesions, our impression is that recurrent tumours have an aggressive look and grow at a rapid pace.

Though we do not have any experience on impression cytology or the proliferation index for these lesions, we appreciate that these two are very sensitive parameters to guide the clinicians regarding recurrences and feel that all ophthalmic departments (at least those of tertiary eye care centres) should have access to these facilities.

We do not agree with the authors' comment that orbital exenteration may be required for control of local disease. Rather we feel, if there is clinical suspicion of intraocular spread the lesions should be subjected to a 20 MHz high frequency ultrasound assessment to check for intraocular involvement and computed tomography to rule out orbital extension before the decision of exenteration. In our series we could save three eyes with optimal visual preservation by performing local excision in cases where previous exenteration had been advised.³ Further, so far we have not come across the problem of death due to metastasis (and we have followed up some patients over 20 years). However, this is a very important issue and all ophthalmologists should remain alert while managing the SCC, more so for extensive lesions.

Finally, we congratulate the authors for their well documented series which, no doubt, will guide the ophthalmic clinicians dealing with these lesions.

A Panda, M S Bajaj, H S Sethi, N Pushker, H Kumar, V K Dada

RP Centre, All India Institute of Medical Sciences, New Delhi, India

Correspondence to: Mandeep S Bajaj, RP Centre, AllMS, Ansari Nagar, New Delhi, 110029 India; msbajaj32@hotmail.com

References

- 1 McKelvie PA, Daniell M, McNab A, *et al*. Squamous cell carcinoma of the conjunctiva: a series of 26 cases. *Br J Ophthalmol* 2002;**86**:168–73.
- 2 Young J, Foster CS. Squamous cell carcinoma of the conjunctiva. *Int Ophthalmol Clin* 1997;**37**:73–85.
- 3 Panda A, Sharma N, Sen S. Massive corneal and conjunctival squamous cell carcinoma. *Ophthalmic Surg Lasers* 2000;**31**:71–2.

NOTICES

Role of optometry in Vision 2000

The latest issue of *Community Eye Health* (No 43) discusses the mobilisation of optometry to deal with uncorrected refractive error, which is now a major cause of functional blindness. For further information please contact: Journal of Community Eye Health, International Centre for Eye Health, Institute of Ophthalmology, 11–43 Bath Street, London EC1V 9EL, UK (tel: +44 (0)20 7608 6910; fax: +44 (0)20

7250 3207; email: eyeresource@ucl.ac.uk; web site: www.jceh.co.uk). Annual subscription (4 issues) UK£25/US\$40. Free to workers in developing countries.

International Centre for Eye Health

The International Centre for Eye Health has published a new edition of the *Standard List of Medicines, Equipment, Instruments and Optical Supplies* (2001) for eye care services in developing countries. It is compiled by the Task Force of the International Agency for the Prevention of Blindness. Further details: Sue Stevens, International Centre for Eye Health, 11–43 Bath Street, London EC1V 9EL, UK (tel: +44 (0)20 7608 6910; email: eyeresource@ucl.ac.uk).

Second Sight

Second Sight, a UK based charity whose aims are to eliminate the backlog of cataract blind in India by the year 2020 and to establish strong links between Indian and British ophthalmologists, is regularly sending volunteer surgeons to India. Details can be found at the charity web site (www.secondsight.org.uk) or by contacting Dr Lucy Mathen (lucymathen@yahoo.com).

Specific Eye ConditionS (SPECs)

Specific Eye ConditionS (SPECs) is a not for profit organisation which acts as an umbrella organisation for support groups of any conditions or syndrome with an integral eye disorder. SPECs represents over fifty different organisations related to eye disorders ranging from conditions that are relatively common to very rare syndromes. We also include groups who offer support of a more general nature to visually impaired and blind people. Support groups meet regularly in the Boardroom at Moorfields Eye Hospital to offer support to each other, share experiences and explore new ways of working together. The web site www.eyecconditions.org.uk acts as a portal giving direct access to support groups own sites. The SPECs web page is a valuable resource for professionals and may also be of interest to people with a visual impairment or who are blind. For further details about SPECs contact: Kay Parkinson, SPECs Development Officer (tel: +44 (0)1803 524238; email: k@eyecconditions.org.uk; web site: www.eyecconditions.org.uk).

The British Retinitis Pigmentosa Society

The British Retinitis Pigmentosa Society (BRPS) was formed in 1975 to bring together people with retinitis pigmentosa and their families. The principle aims of BRPS are to raise funds to support the programme of medical research into an eventual cure for this hereditary disease, and through the BRPS welfare service, help members and their families cope with the everyday concerns caused by retinitis pigmentosa. Part of the welfare service is the telephone helpline (+44 (0)1280 860 363), which is a useful resource for any queries or worries relating to the problems retinitis pigmentosa can bring. This service is especially valuable for those recently diagnosed with retinitis pigmentosa, and all calls are taken in the strictest confidence. Many people with retinitis pigmentosa have found the Society helpful, providing encouragement, and support through the Helpline, the welfare network and the BRPS branches

throughout the UK. (tel: +44 (0)1280 821 334; email: lynda@brps.demon.co.uk; web site: www.brps.demon.co.uk)

The International Strabismological Association Fellowship

The International Strabismological Association (ISA) has established one fellowship for either basic or advanced training in strabismus/paediatric ophthalmology supported in the amount of \$10 000 (US). Applications may be obtained from the Secretary/Treasurer of the ISA, Derek T Springer, MD, at Indiana University School of Medicine, 702 Rotary Circle, Indianapolis, Indiana 46202 (email: isa.lms@juno.com). The last day for this application is 15 January 2003.

Retinal Detachment Course with international faculty and case presentations preceding Vitrektomie-Kurs—Wetlab

The Retinal Detachment Course with international faculty and case presentations and Vitrektomie-Kurs—Wetlab will be held 13 February 2003 (in English) and 14–15 February 2003 (in German) respectively, at Verwaltungsgebäude der KA Rudolfstiftung, 1030 Vienna, Boerhaavegasse 8a, Austria. Further details and registration: Firma Askin & Co, Albert-Schweritzer-Gasse 6, A-1140 Vienna, Austria (tel: +43 (1) 979 88 44; fax: +43 (1) 979 88 46).

Detachment Course with international faculty on: Retinal and Vitreous Surgery with Case Presentations preceding Retina Meeting

The detachment course with international faculty on: Retinal and Vitreous Surgery with Case Presentations and the Retina Meeting

will be held 14–15 March 2003 and 16 March 2003 respectively, in Mexico City, Mexico. Further details: Scientific programme: Prof Ingrid Kreissig, University of Tuebingen, Schleichstr. 12, Breuningerbau, 72076 Tuebingen, Germany (tel: +49 7071 295209; email: ingrid.kreissig@med.uni-tuebingen.de).

Local organisation: Prof. Quiroz-Mercado, Prof. Munoz, and Prof. Gonzalez "Hospital Luis Sanchez Bulnes", Asociacion para Evitar la Ceguera en Mexico Vicente Garcia Torres #46, Coyoacan, Mexico DF 04330 (fax: +5255 5659 5928; email: retinamex@yahoo.com).

16th Annual Meeting of German Ophthalmic Surgeons

The 16th Annual Meeting of German Ophthalmic Surgeons will be held 8–11 May 2003 in Nürnberg, Germany, Messezentrum. Organised by the Professional Association of German Ophthalmologists Ophthalmic Surgery Group the conference will cover cataract surgery, refractive surgery, glaucoma surgery, vitreoretinal surgery, corneal surgery, eye surgery in developing countries, and orbita, lacrimal and lid surgery. Further details: MCN Medizinische Congress organisation Nürnberg AG, Zerkabelshofstr 29, 90478 Nürnberg, Germany (tel: +49 911 3931621; fax: +49 911 3931620; email: doc@mcnag.info; web site: www.doc-nuernberg.de).

13th Meeting of the EASD Eye Complication Study Group

The 13th Meeting of the EASD Eye Complication Study Group will be held on the 23–25 May 2003, in Prague, Czech Republic. The scientific programme includes keynote lectures from Professor John H Fuller (UK) on The epidemiology of diabetic retinopathy; Dr P Martin van Hagen (The Netherlands) on Growth factors and diabetic retinopathy; Professor Terezie Pelikanova (Czech Republic) on Pathophysiology of diabetic microvascular

complications; Dr Tomas Sosna (Czech Republic) on Risk and protective factors of diabetic retinopathy.

Three travel grants of €1000 each, sponsored by GlaxoSmithKline for young scientists (under 35 years at the time of the meeting). Applications should be made with the submission of abstracts. The deadline for abstracts is 14 February 2003.

Further details: Ortopedicke Centrum, s.r.o., Strekovské nabřeží 51, 400 03 Usti nad Labem, Czech Republic (tel: +420 47 521 6588; fax: +420 47 533 40 77; email: ortocentrum-ul@volny.cz; web site: www.ortopedicke-centrum.cz).

Detachment Course with international faculty on: Retinal and Vitreous Surgery with Case Presentations preceding the Annual Meeting of Iranian Society of Ophthalmology

The detachment course with international faculty on: Retinal and Vitreous Surgery with Case Presentations preceding Annual Meeting of Iranian Society of Ophthalmology will be held on 29–30 November 2003 and 1–4 December 2003 respectively, at the Razi Conference Center, Hemmat Hyw, Tehran, Iran. Further details: Scientific programme: Prof Ingrid Kreissig, University of Tuebingen, Schleichstr. 12, Breuningerbau, 72076 Tuebingen, Germany (tel: +49 7071 295209; email: ingrid.kreissig@med.uni-tuebingen.de). Local organisation: Dr Arman Masheyekhi, Dr Siamak Moradian, Dept of Ophthalmology, Labbanfinejad Medical Center, Pasdaran Ave, Boostan 9, Tehran, 16666, Iran (fax: +98 21 254 9039; email: labbafi@hotmail.com).